# EDGAR Filing Document

**Accession Number:** 0001516513
**File Stem:** 0001516513-25-000111
**Filing Date:** 2025-11
**Character Count:** 186281
**Document Hash:** b3acb8780b84a7f333d24146838c6d65
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001516513-25-000111.hdr.sgml**: 20251106

**ACCESSION NUMBER**: 0001516513-25-000111

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 90

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251106

**DATE AS OF CHANGE**: 20251106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Doximity, Inc.
- **CENTRAL INDEX KEY:** 0001516513
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROGRAMMING SERVICES [7371]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 272485512
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40508
- **FILM NUMBER:** 251458442

**BUSINESS ADDRESS:**
- **STREET 1:** 500 THIRD STREET, SUITE 510
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94107
- **BUSINESS PHONE:** (650) 549-4330

**MAIL ADDRESS:**
- **STREET 1:** 500 THIRD STREET, SUITE 510
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94107

?xml version='1.0' encoding='ASCII'? docs-20250930

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

_________________________________________________________________________________________________________________

**FORM 10-Q**

_________________________________________________________________________________________________________________

**(Mark One)**

**☒** **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended September 30, 2025**

**OR**

**☐** **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from to** 

**Commission file number 001-40508**

_________________________________________________________________________________________________________________

**Doximity, Inc.**

(Exact Name of Registrant as Specified in its Charter)

_________________________________________________________________________________________________________________

---

| | |
|:---|:---|
| **Delaware** | **27-2485512** |
| (State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification Number) |
| **500 3rd St.**<br>**Suite 510**<br>**San Francisco, CA 94107**<br>(Address of principal executive offices, including zip code) | **500 3rd St.**<br>**Suite 510**<br>**San Francisco, CA 94107**<br>(Address of principal executive offices, including zip code) |
| **(650) 549-4330**<br>(Registrant's telephone number, including area code) | **(650) 549-4330**<br>(Registrant's telephone number, including area code) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of exchange on which registered** |
| Class A common stock, $0.001 par value per share | DOCS | The New York Stock Exchange |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer  | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| | | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

The registrant had outstanding 137,373,858 shares of Class A common stock and 50,897,411 shares of Class B common stock as of October 30, 2025.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| | **<u>[Part I—Financial Information](#i9f5d1bf567c643aa8f278e421a5a7845_13)</u>** | **Page** |
| **<u>[Item 1.](#i9f5d1bf567c643aa8f278e421a5a7845_16)</u>** | **<u>[Condensed Consolidated Financial Statements (Unaudited)](#i9f5d1bf567c643aa8f278e421a5a7845_16)</u>:** | |
| | **<u>[Condensed Consolidated Balance Sheets as of September 30, 2025 and March 31, 2025](#i9f5d1bf567c643aa8f278e421a5a7845_19)</u>** | &nbsp;&nbsp;<u>[1](#i9f5d1bf567c643aa8f278e421a5a7845_19)</u> |
| | **<u>[Condensed Consolidated Statements of Operations for the three and six months ended September 30, 2025 and 2024](#i9f5d1bf567c643aa8f278e421a5a7845_22)</u>** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[2](#i9f5d1bf567c643aa8f278e421a5a7845_22)</u> |
| | **<u>[Condensed Consolidated Statements of Comprehensive Income for the three and six months ended September 30, 2025 and 2024](#i9f5d1bf567c643aa8f278e421a5a7845_25)</u>** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[3](#i9f5d1bf567c643aa8f278e421a5a7845_25)</u> |
| | **<u>[Condensed Consolidated Statements of Stockholders' Equity for the three and six months ended September 30, 2025 and 2024](#i9f5d1bf567c643aa8f278e421a5a7845_28)</u>** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[4](#i9f5d1bf567c643aa8f278e421a5a7845_28)</u> |
| | **<u>[Condensed Consolidated Statements of Cash Flows for the six months ended September 30, 2025 and 2024](#i9f5d1bf567c643aa8f278e421a5a7845_31)</u>** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[6](#i9f5d1bf567c643aa8f278e421a5a7845_31)</u> |
| | **<u>[Notes to Condensed Consolidated Financial Statements](#i9f5d1bf567c643aa8f278e421a5a7845_34)</u>** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[7](#i9f5d1bf567c643aa8f278e421a5a7845_34)</u> |
| **<u>[Item 2.](#i9f5d1bf567c643aa8f278e421a5a7845_85)</u>** | **<u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i9f5d1bf567c643aa8f278e421a5a7845_85)</u>** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[27](#i9f5d1bf567c643aa8f278e421a5a7845_85)</u> |
| **<u>[Item 3.](#i9f5d1bf567c643aa8f278e421a5a7845_112)</u>** | **<u>[Quantitative and Qualitative Disclosures about Market Risk](#i9f5d1bf567c643aa8f278e421a5a7845_112)</u>** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[37](#i9f5d1bf567c643aa8f278e421a5a7845_112)</u> |
| **<u>[Item 4.](#i9f5d1bf567c643aa8f278e421a5a7845_115)</u>** | **<u>[Controls and Procedures](#i9f5d1bf567c643aa8f278e421a5a7845_115)</u>** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[37](#i9f5d1bf567c643aa8f278e421a5a7845_115)</u> |
| | **<u>[Part II—Other Information](#i9f5d1bf567c643aa8f278e421a5a7845_118)</u>** | |
| **<u>[Item 1.](#i9f5d1bf567c643aa8f278e421a5a7845_121)</u>** | **<u>[Legal Proceedings](#i9f5d1bf567c643aa8f278e421a5a7845_121)</u>** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[39](#i9f5d1bf567c643aa8f278e421a5a7845_121)</u> |
| **<u>[Item 1A.](#i9f5d1bf567c643aa8f278e421a5a7845_124)</u>** | **<u>[Risk Factors](#i9f5d1bf567c643aa8f278e421a5a7845_124)</u>** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[39](#i9f5d1bf567c643aa8f278e421a5a7845_124)</u> |
| **<u>[Item 2.](#i9f5d1bf567c643aa8f278e421a5a7845_127)</u>** | **<u>[Unregistered Sales of Equity Securities and Use of Proceeds](#i9f5d1bf567c643aa8f278e421a5a7845_127)</u>** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[40](#i9f5d1bf567c643aa8f278e421a5a7845_127)</u> |
| **<u>[Item 3.](#i9f5d1bf567c643aa8f278e421a5a7845_130)</u>** | **<u>[Defaults Upon Senior Securities](#i9f5d1bf567c643aa8f278e421a5a7845_130)</u>** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[41](#i9f5d1bf567c643aa8f278e421a5a7845_130)</u> |
| **<u>[Item 4.](#i9f5d1bf567c643aa8f278e421a5a7845_133)</u>** | **<u>[Mine Safety Disclosures](#i9f5d1bf567c643aa8f278e421a5a7845_133)</u>** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[41](#i9f5d1bf567c643aa8f278e421a5a7845_133)</u> |
| **<u>[Item 5.](#i9f5d1bf567c643aa8f278e421a5a7845_136)</u>** | **<u>[Other Information](#i9f5d1bf567c643aa8f278e421a5a7845_136)</u>** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[41](#i9f5d1bf567c643aa8f278e421a5a7845_136)</u> |
| **<u>[Item 6.](#i9f5d1bf567c643aa8f278e421a5a7845_142)</u>**  | **<u>[Exhibits](#i9f5d1bf567c643aa8f278e421a5a7845_142)</u>** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[42](#i9f5d1bf567c643aa8f278e421a5a7845_142)</u> |
| | **<u>[Signatures](#i9f5d1bf567c643aa8f278e421a5a7845_145)</u>** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[43](#i9f5d1bf567c643aa8f278e421a5a7845_145)</u> |

---

&nbsp;&nbsp;&nbsp;&nbsp;

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws, which are statements that involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "shall," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," or "continue" or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans, or intentions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our expectations regarding our revenue, expenses, and other operating results;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our future financial performance;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our expectations and management of future growth;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to acquire new members and successfully retain existing members;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to acquire new customers and successfully retain existing customers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to achieve or maintain our profitability;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• future investments in our business, our anticipated capital expenditures, and our estimates regarding our capital requirements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the costs and success of our sales and marketing efforts, and our ability to promote our brand;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to effectively manage our growth, including our ability to identify, retain, and recruit personnel, and maintain our culture;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to comply with laws and regulations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to successfully defend litigation brought against us;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to maintain, protect, and enhance our intellectual property rights and any costs associated therewith;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to maintain data privacy and data security;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to respond to rapid technological changes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our expectations regarding the impact of uncertainty in the current economic environment and macroeconomic uncertainty;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to compete effectively with existing competitors and new market entrants;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the growth rates of the markets in which we compete;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the increased expenses associated with being a public company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of any cost-savings or restructuring activities we may undertake in the future;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the sufficiency of our cash and cash equivalents and marketable securities to meet our liquidity needs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to comply with modified or new laws and regulations applying to our business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to successfully identify, acquire, and integrate companies and assets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• developments and projections relating to our competitors and our industry, including competing solutions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• impact from future regulatory, judicial, and legislative changes or developments that may affect our customers' or our business; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the risks related to our Class A common stock and our dual class common stock structure.

We caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report on Form 10-Q.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

You should not rely upon forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this Quarterly Report on Form 10-Q primarily on our current expectations and projections about future events and trends that we believe may affect our business, results of operations, financial condition, and prospects. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties, and other factors described in the section titled "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended March 31, 2025 filed with the Securities and Exchange Commission, the SEC, on May 20, 2025, and elsewhere in this Quarterly Report on Form 10-Q, as well as in our other filings with the SEC. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q. The results, events, and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events, or circumstances could differ materially from those described in the forward-looking statements.

The forward-looking statements made in this Quarterly Report on Form 10-Q relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Quarterly Report on Form 10-Q to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments we may make.

In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**PART I—FINANCIAL INFORMATION**

**Item 1. Condensed Consolidated Financial Statements (Unaudited)**

**DOXIMITY, INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(in thousands, except per share data)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **March 31, 2025** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $169249 | $209614 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Marketable securities | 709118 | 706050 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowance for doubtful accounts of $1,508 and $1,937 at September 30, 2025 and March 31, 2025, respectively | 129306 | 128354 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 84527 | 44602 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 1092200 | 1088620 |
| Property and equipment, net | 15712 | 13656 |
| Deferred income tax assets | 15074 | 60014 |
| Operating lease right-of-use assets | 7982 | 8886 |
| Intangible assets, net | 39143 | 23072 |
| Goodwill | 84973 | 67940 |
| Other assets | 2025 | 2121 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $1257109 | $1264309 |
| **Liabilities and Stockholders' Equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $4391 | $1356 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 33722 | 38405 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue, current | 100034 | 114285 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities, current | 2123 | 2211 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 140270 | 156257 |
| Deferred revenue, non-current | 263 | 280 |
| Operating lease liabilities, non-current | 9146 | 10185 |
| Contingent earn-out consideration liability, non-current |  | 5579 |
| Other liabilities, non-current | 11899 | 9383 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 161578 | 181684 |
| Commitments and contingencies (Note 13) |  |  |
| **Stockholders' Equity** |  |  |
| Preferred stock, $0.001 par value; 100,000 shares authorized as of September 30, 2025 and March 31, 2025, respectively; zero shares issued and outstanding as of September 30, 2025 and March 31, 2025, respectively |  |  |
| Class A and Class B common stock, $0.001 par value; 1,500,000 shares authorized as of September 30, 2025 and March 31, 2025, respectively; 188,090 and 188,875 shares issued and outstanding as of September 30, 2025 and March 31, 2025, respectively | 188 | 189 |
| Additional paid-in capital | 936176 | 894225 |
| Accumulated other comprehensive income | 1477 | 1323 |
| Retained earnings | 157690 | 186888 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 1095531 | 1082625 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $1257109 | $1264309 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(in thousands, except per share data)**

**(unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Six Months Ended September 30,** | **Six Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Revenue | $168525 | $136832 | $314438 | $263508 |
| Cost of revenue | 16425 | 13676 | 32218 | 27226 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 152100 | 123156 | 282220 | 236282 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development | 30202 | 23240 | 57001 | 45814 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | 39168 | 34367 | 75533 | 69611 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 19049 | 10103 | 31488 | 19358 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment charge |  | 2304 |  | 2304 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 88419 | 70014 | 164022 | 137087 |
| Income from operations | 63681 | 53142 | 118198 | 99195 |
| Other income, net | 9258 | 9029 | 18888 | 16145 |
| Income before income taxes | 72939 | 62171 | 137086 | 115340 |
| Provision for income taxes | 10880 | 18017 | 21707 | 29809 |
| Net income | $62059 | $44154 | $115379 | $85531 |
| Net income per share attributable to Class A and Class B common stockholders: |  |  |  |  |
| Basic | $0.33 | $0.24 | $0.61 | $0.46 |
| Diluted | $0.31 | $0.22 | $0.57 | $0.43 |
| Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders: |  |  |  |  |
| Basic | 187705 | 186252 | 187844 | 185933 |
| Diluted | 200745 | 200407 | 200952 | 199818 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

**(in thousands)**

**(unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Six Months Ended September 30,** | **Six Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net income | $62059 | $44154 | $115379 | $85531 |
| Other comprehensive income |  |  |  |  |
| Change in unrealized gain on available-for-sale-securities, net of tax provision of $99, $1,246, $52, and $1,803, respectively | 294 | 3684 | 154 | 5340 |
| Comprehensive income | $62353 | $47838 | $115533 | $90871 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

**(in thousands)**

**(unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** | **Three Months Ended September 30, 2025** |
| | **Class A and Class B <br>Common Stock** | **Class A and Class B <br>Common Stock** | **Additional Paid-In<br>Capital** | **Accumulated Other Comprehensive Income** | **Retained Earnings** | **Stockholders' Equity** |
| | **Shares** | **Amount** | **Additional Paid-In<br>Capital** | **Accumulated Other Comprehensive Income** | **Retained Earnings** | **Stockholders' Equity** |
| **Balance as of June 30, 2025** | 187453 | $187 | $907115 | $1183 | $117110 | $1025595 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation |  |  | 26484 |  |  | 26484 |
| &nbsp;&nbsp;&nbsp;&nbsp;Exercise of stock options and common stock warrants | 580 | 1 | 2427 |  |  | 2428 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vesting of restricted stock units, net of shares withheld for taxes | 379 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax withholding on shares under stock-based compensation awards |  |  | (12566) |  |  | (12566) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase and retirement of common stock, including excise tax | (355) |  |  |  | (21479) | (21479) |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock warrant expense |  |  | 1350 |  |  | 1350 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of common stock in connection with the employee stock purchase plan | 33 |  | 1816 |  |  | 1816 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity awards included in purchase consideration |  |  | 9550 |  |  | 9550 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income |  |  |  | 294 |  | 294 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income |  |  |  |  | 62059 | 62059 |
| **Balance as of September 30, 2025** | 188090 | $188 | $936176 | $1477 | $157690 | $1095531 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** | **Three Months Ended September 30, 2024** |
| | **Class A and Class B <br>Common Stock** | **Class A and Class B <br>Common Stock** | **Additional Paid-In<br>Capital** | **Accumulated Other Comprehensive Income (Loss)** | **Retained Earnings** | **Stockholders' Equity** |
| | **Shares** | **Amount** | **Additional Paid-In<br>Capital** | **Accumulated Other Comprehensive Income (Loss)** | **Retained Earnings** | **Stockholders' Equity** |
| **Balance as of June 30, 2024** | 185704 | $186 | $841470 | $(1008) | $72932 | $913580 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation |  |  | 16992 |  |  | 16992 |
| &nbsp;&nbsp;&nbsp;&nbsp;Exercise of stock options and common stock warrants | 1441 | 1 | 7707 |  |  | 7708 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vesting of restricted stock units, net of shares withheld for taxes | 321 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax withholding on shares under stock-based compensation awards |  |  | (5828) |  |  | (5828) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase and retirement of common stock, including excise tax | (740) |  |  |  | (21866) | (21866) |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock warrant expense |  |  | 1350 |  |  | 1350 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of common stock in connection with the employee stock purchase plan | 55 |  | 1422 |  |  | 1422 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income |  |  |  | 3684 |  | 3684 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income |  |  |  |  | 44154 | 44154 |
| **Balance as of September 30, 2024** | 186781 | $187 | $863113 | $2676 | $95220 | $961196 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY**

**(in thousands)**

**(unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Six Months Ended September 30, 2025** | **Six Months Ended September 30, 2025** | **Six Months Ended September 30, 2025** | **Six Months Ended September 30, 2025** | **Six Months Ended September 30, 2025** | **Six Months Ended September 30, 2025** |
| | **Class A and Class B <br>Common Stock** | **Class A and Class B <br>Common Stock** | **Additional Paid-In<br>Capital** | **Accumulated Other Comprehensive Income** | **Retained Earnings** | **Stockholders' Equity** |
| | **Shares** | **Amount** | **Additional Paid-In<br>Capital** | **Accumulated Other Comprehensive Income** | **Retained Earnings** | **Stockholders' Equity** |
| **Balance as of March 31, 2025** | 188875 | $189 | $894225 | $1323 | $186888 | $1082625 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation |  |  | 47569 |  |  | 47569 |
| &nbsp;&nbsp;&nbsp;&nbsp;Exercise of stock options and common stock warrants | 1081 | 2 | 4824 |  |  | 4826 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vesting of restricted stock units, net of shares withheld for taxes | 722 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax withholding on shares under stock-based compensation awards |  |  | (24493) |  |  | (24493) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase and retirement of common stock, including excise tax | (2621) | (3) |  |  | (144577) | (144580) |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock warrant expense |  |  | 2685 |  |  | 2685 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of common stock in connection with the employee stock purchase plan | 33 |  | 1816 |  |  | 1816 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity awards included in purchase consideration |  |  | 9550 |  |  | 9550 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income |  |  |  | 154 |  | 154 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income |  |  |  |  | 115379 | 115379 |
| **Balance as of September 30, 2025** | 188090 | $188 | $936176 | $1477 | $157690 | $1095531 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Six Months Ended September 30, 2024** | **Six Months Ended September 30, 2024** | **Six Months Ended September 30, 2024** | **Six Months Ended September 30, 2024** | **Six Months Ended September 30, 2024** | **Six Months Ended September 30, 2024** |
| | **Class A and Class B <br>Common Stock** | **Class A and Class B <br>Common Stock** | **Additional Paid-In<br>Capital** | **Accumulated Other Comprehensive Income (Loss)** | **Retained Earnings** | **Stockholders' Equity** |
| | **Shares** | **Amount** | **Additional Paid-In<br>Capital** | **Accumulated Other Comprehensive Income (Loss)** | **Retained Earnings** | **Stockholders' Equity** |
| **Balance as of March 31, 2024** | 186562 | $187 | $823885 | $(2664) | $79989 | $901397 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation |  |  | 33089 |  |  | 33089 |
| &nbsp;&nbsp;&nbsp;&nbsp;Exercise of stock options and common stock warrants | 2225 | 2 | 10254 |  |  | 10256 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vesting of restricted stock units, net of shares withheld for taxes | 532 |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax withholding on shares under stock-based compensation awards |  |  | (8222) |  |  | (8222) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase and retirement of common stock, including excise tax | (2593) | (2) |  |  | (70300) | (70302) |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock warrant expense |  |  | 2685 |  |  | 2685 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of common stock in connection with the employee stock purchase plan | 55 |  | 1422 |  |  | 1422 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income |  |  |  | 5340 |  | 5340 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income |  |  |  |  | 85531 | 85531 |
| **Balance as of September 30, 2024** | 186781 | $187 | $863113 | $2676 | $95220 | $961196 |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(in thousands)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **Six Months Ended September 30,** | **Six Months Ended September 30,** |
| | **2025** | **2024** |
| **Cash flows from operating activities** |  |  |
| Net income | $115379 | $85531 |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;Depreciation and amortization | 6263 | 5175 |
| &nbsp;&nbsp;Deferred income taxes |  | 204 |
| &nbsp;&nbsp;Stock-based compensation, net of amounts capitalized | 51339 | 34958 |
| &nbsp;&nbsp;Non-cash lease expense | 904 | 951 |
| &nbsp;&nbsp;Accretion of discount on marketable securities, net | (4687) | (5368) |
| &nbsp;&nbsp;Amortization of deferred contract costs | 6772 | 4759 |
| &nbsp;&nbsp;Impairment of long-lived assets |  | 2304 |
| &nbsp;&nbsp;Other | (114) | (122) |
| &nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (985) | (23478) |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | 3451 | 19948 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred contract costs | (4549) | (3216) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable, accrued expenses and other liabilities | (2333) | (5546) |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | (14268) | (5457) |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | (1127) | (1054) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by operating activities** | 156045 | 109589 |
| **Cash flows from investing activities** |  |  |
| Cash paid for acquisition, net of cash acquired | (26528) |  |
| Internal-use software development costs | (4335) | (3247) |
| Purchases of marketable securities | (268200) | (367808) |
| Maturities of marketable securities | 270031 | 417913 |
| Sales of marketable securities |  | 7241 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by (used in) investing activities** | (29032) | 54099 |
| **Cash flows from financing activities** |  |  |
| Proceeds from issuance of common stock upon exercise of stock options and common stock warrants | 4796 | 10243 |
| Proceeds from issuance of common stock in connection with the employee stock purchase plan | 1816 | 1422 |
| Taxes paid related to net share settlement of equity awards | (24493) | (8222) |
| Repurchase of common stock | (144248) | (74198) |
| Payment of contingent consideration related to a business combination | (5249) | (5470) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash used in financing activities** | (167378) | (76225) |
| Net increase (decrease) in cash and cash equivalents | (40365) | 87463 |
| Cash and cash equivalents, beginning of period | 209614 | 96785 |
| **Cash and cash equivalents, end of period**  | $169249 | $184248 |
| **Supplemental disclosures of cash flow information** |  |  |
| &nbsp;&nbsp;Cash paid for taxes, net of refunds | $19347 | $21985 |
| **Non-cash financing and investing activities** |  |  |
| Equity awards included in purchase consideration | $9550 | $— |

---

The accompanying notes are an integral part of these condensed consolidated financial statements.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS** 

**(unaudited)** 

**1. Description of Business**

Doximity, Inc. (the "Company") was incorporated in the state of Delaware in April 2010 as 3MD Communications, Inc. and is headquartered in San Francisco, California. The Company subsequently changed its name to Doximity, Inc. in June 2010. The Company provides an online platform, which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers primarily include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Marketing Solutions provide customers with the ability to share tailored content on the network. Hiring Solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates. Workflow Solutions allow customers to securely initiate voice and video calls with patients, manage on-call scheduling, and leverage the artificial intelligence ("AI") writing assistant for administrative tasks and clinical decision support.

**2. Summary of Significant Accounting Policies**

There have been no material changes to the significant accounting policies of the Company during the six months ended September 30, 2025 as compared to those described in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2025 and filed with the SEC on May 20, 2025.

***Basis of Presentation and Principles of Consolidation***

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") and applicable rules and regulations of the U.S. Securities and Exchange Commission ("SEC") regarding interim financial reporting. Accordingly, they do not include all disclosures normally required in annual consolidated financial statements prepared in accordance with U.S. GAAP. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2025.

The accompanying condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of the Company's management, the information contained herein reflects all adjustments necessary for a fair presentation of the Company's financial position, results of operations, stockholders' equity, and cash flows. The results of operations for the three and six months ended September 30, 2025, shown in this report are not necessarily indicative of the results to be expected for the full year ending March 31, 2026.

***Fiscal Year***

The Company's fiscal year ends on March 31<sup>st</sup>. Unless otherwise noted, all references to a particular year shall mean the Company's fiscal year.

***Use of Estimates***

The preparation of the Company's condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts stated in the condensed consolidated financial statements and accompanying notes. These judgments, estimates, and assumptions are used for, but not limited to, revenue recognition, the fair values of acquired intangible assets and goodwill, the useful lives of long-lived assets, fair value of contingent earn-out consideration, and deferred income taxes. The Company bases its estimates on historical experience and on assumptions that management considers reasonable. The Company assesses these estimates on a regular basis; however, actual results could differ from these estimates due to risks and uncertainties, including uncertainty in the current economic environment.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)** 

***Concentrations of Credit Risk***

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, and accounts receivable. The primary focus of the Company's investment strategy is to preserve capital and meet liquidity requirements. The Company's investment policy addresses the level of credit exposure by limiting the concentration in any one corporate issuer or sector and establishing a minimum allowable credit rating. To manage risk exposure, the Company invests cash equivalents and marketable securities in a variety of fixed income securities, including government and investment-grade debt securities and money market funds. The Company places its cash primarily in checking and money market accounts with reputable financial institutions. Deposits held with these financial institutions may exceed the amount of insurance provided on such deposits, if any.

Concentrations of credit risk with respect to accounts receivable are primarily limited to certain customers to which the Company makes substantial sales. The Company's significant customers that represented 10% or more of revenue or accounts receivable, net for the periods presented were as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Revenue** | **Revenue** | **Revenue** | **Revenue** | **Accounts Receivable, Net** | **Accounts Receivable, Net** |
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Six Months Ended September 30,** | **Six Months Ended September 30,** | **September 30, 2025** | **March 31, 2025** |
| | **2025** | **2024** | **2025** | **2024** | **September 30, 2025** | **March 31, 2025** |
| Customer A | \* | \* | \* | \* | \* | 12% |
| Customer B | \* | \* | \* | \* | 12% | \* |
| Customer C | \* | \* | \* | \* | 10% | \* |
| Customer D | 11% | \* | 11% | \* | \* | \* |

---

_______________

\* Less than 10%

For the purpose of assessing the concentration of credit risk for significant customers, the Company defines a customer as an entity that purchases the Company's services directly or indirectly through marketing agencies.

***Accounting Pronouncements Recently Adopted***

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses on an annual and interim basis. The standard was effective for the Company for its fiscal year beginning April 1, 2024, and for interim periods within the fiscal year beginning April 1, 2025. The Company adopted ASU 2023-07 retrospectively during the fiscal year ended March 31, 2025. See Note 17—Segment and Geographic Information in the accompanying notes to the condensed consolidated financial statements for further detail.

***Accounting Pronouncements Not Yet Adopted***

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which includes amendments that further enhance annual income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The amendments are effective for the Company's annual periods beginning April 1, 2025, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating the impact of this ASU on its consolidated financial statements.

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires the disaggregation of certain expenses in the notes of the financials to provide enhanced transparency into the expense captions presented on the face of the income statement. This ASU is effective for the Company for its fiscal year beginning April 1, 2027, and for interim periods within the fiscal year beginning April 1, 2028, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating the impact of this ASU on its consolidated financial statement disclosures.

In July 2025, the FASB issued ASU 2025-05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which provides a practical expedient related to the estimation of expected

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)** 

credit losses for current accounts receivable and current contract assets to reduce complexity for the measurement of credit losses arising from transactions accounted for under ASC 606. The practical expedient permits the entity to assume that current conditions as of the balance sheet date do not change for the remaining life of the asset. ASU 2025-05 is effective for the Company for its fiscal year beginning on April 1, 2026, with early adoption permitted and any amendments should be applied prospectively. The Company is currently evaluating the impact of this ASU on its consolidated financial statement disclosures and believes that the adoption will not have a material impact on the consolidated financial statements and related disclosures.

In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which provides modernized guidance for the recognition and disclosure framework for internal-use software costs. This amendment removes all prescriptive and sequential software development stages and clarifies the threshold of when the Company is required to start capitalizing software costs, which commences when management has authorized and committed to funding the project and it is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for the Company for its fiscal year beginning on April 1, 2028, with early adoption permitted. The amendments in this ASU should be applied either prospectively, retrospectively, or utilizing a modified transition approach based on status of project. The Company is currently evaluating the impact of this ASU on its consolidated financial statement disclosures.

**3. Revenue Recognition**

The Company's revenue is primarily derived from the sale of subscriptions for the following solutions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Marketing Solutions*: Hosting of customer-sponsored content on the Doximity platform and providing access to the Company's professional database of healthcare professionals for referral or marketing purposes during the subscription period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Hiring Solutions*: Providing customers access to the Company's professional tools where recruiters can access the Company's database of healthcare professionals, allowing customers to send messages for talent sourcing and to share job postings during the subscription period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Workflow Solutions*: Offering health systems and hospitals various tools for telehealth, on-call scheduling, and the AI writing assistant during the subscription period.

The Company recognizes revenue through the following five steps:

*1) Identify the contract with a customer*

The Company considers the terms and conditions of its contracts and the Company's customary business practices in identifying its contracts under ASC 606. The Company determines it has a contract with a customer when the contract has been approved by both parties, it can identify each party's rights regarding the services to be transferred and the payment terms for the services, it has determined that the customer has the ability and intent to pay, and the contract has commercial substance. At contract inception, the Company evaluates whether two or more contracts should be combined and accounted for as a single contract. The Company applies judgment in determining the customer's ability and intent to pay, which is based on a variety of factors, including the customer's payment history or, in the case of a new customer, the customer's credit and financial information.

Contractual terms for Marketing Solutions contracts are generally 12 months or less. Customers are generally billed for a portion of the contract upon contract execution and then billed throughout the remainder of the contract based on various time-based milestones. Certain Marketing Solutions contracts are cancelable with a customary notice period. The Company does not refund customer payments, and customers are responsible for amounts invoiced where payment was not made upon cancellation. The contractual term for Hiring and Workflow Solutions contracts is generally 12 months. Hiring and Workflow Solutions contracts are noncancelable and customers are billed in annual, quarterly, or monthly installments in advance of the service period.

*2) Identify the performance obligations in the contract*

Performance obligations promised in a contract are identified based on the services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the service either on its own or together with

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)** 

other resources that are readily available, and are distinct in the context of the contract, whereby the transfer of the services is separately identifiable from other promises in the contract.

Marketing Solutions customers may purchase a subscription for a specific module to be used over a defined period of time. These customers may purchase more than one module with either the same or different subscription periods. Modules are the core building blocks of the customers' marketing plan and can be broadly categorized as Newsfeed, Workflow, and Peer. As an example, the Company's Newsfeed modules may include a sponsored article, short animated videos or other short-form content that is presented to the targeted member.

Each module targets a consistent number of Doximity members per month for the duration of the subscription period. The Company treats each subscription to a specific module as a distinct performance obligation because each module is capable of being distinct as the customer can benefit from the subscription to each module on their own and each subscription can be sold standalone. Furthermore, the subscriptions to individual modules are distinct in the context of the contract as (1) the Company is not integrating the services with other services promised in the contract into a bundle of services that represent a combined output, (2) the subscriptions to specific modules do not significantly modify or customize the subscription to another module, and (3) the specific modules are not highly interdependent or highly interrelated. The subscription to each module is treated as a series of distinct performance obligations because it is distinct and substantially the same, satisfied over time, and has the same measure of progress.

Marketing Solutions customers may also purchase integrated and other subscriptions for a fixed fee that are not tied to a single module per month but allow customers to utilize a given module or combination of modules during the subscription period, subject to limits on the total number of modules launched in a given period of time, active at any given time, and members targeted. These represent stand-ready obligations in that the delivery of the underlying sponsored content is within the control of the customer and the extent of use in any given period does not diminish the remaining services.

Subscriptions to Hiring Solutions provide customers access to the platform to place targeted job postings and send a fixed number of monthly messages. Workflow Solutions subscriptions grant customers access to telehealth tools, on-call scheduling, and the AI writing assistant for a specified number of users throughout the subscription period. Each subscription is treated as a series of distinct performance obligations that are satisfied over time.

*3) Determine the transaction price* 

The transaction price is determined based on the consideration the Company expects to be entitled to in exchange for transferring services to the customer. Variable consideration is included in the transaction price if, in the Company's judgment, it is probable that a significant future reversal of cumulative revenue recognized under the contract will not occur.

The Company may generate sales through the use of third-party media agencies that are authorized to enter into contracts on behalf of an end customer. The Company acts as the principal in these transactions since it maintains control prior to transferring the service to the customer and is primarily responsible for the fulfillment that occurs through the Company's platform. The Company records revenue for the amount to which it is entitled from the third-party media agencies as the Company does not know and expects not to know the price charged by the third-party media agencies to its customers.

Revenue is recognized net of any taxes collected from customers, which are subsequently remitted to governmental entities.

*4) Allocate the transaction price to performance obligations in the contract*

If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative stand-alone selling price ("SSP"). The determination of a SSP for each distinct performance obligation requires judgment. The Company determines SSP for performance obligations based on historical arrangements sold on a standalone basis. To the extent historical sales are not available or do not provide sufficient evidence, the Company estimates the SSP by taking into account overall pricing objectives, which take into consideration market conditions and customer-specific factors, including a review of internal discounting tables, the type of services being sold, and other factors.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)** 

*5) Recognize revenue when or as the Company satisfies a performance obligation*

Revenue is recognized when or as control of the promised goods or service is transferred to the customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. Subscriptions represent a series of distinct goods or services because the performance obligations are satisfied over time as customers simultaneously receive and consume the benefits related to the services as the Company performs. In the case of module specific subscriptions, a consistent level of service is provided during each monthly period the sponsored content is available on the Company's platform. The Company commences revenue recognition when the first content is launched on the platform for the initial monthly period and revenue is recognized over time as each subsequent content period is delivered. The Company's obligation for its integrated and other Marketing Solutions subscriptions is to stand-ready throughout the subscription period; therefore, for these subscriptions, we record revenue ratably over the subscription period commencing with either the beginning of the subscription term or first launch.

The Company treats Hiring and Workflow Solutions subscriptions as a single performance obligation that represents a series of distinct performance obligations that is satisfied over time. Revenue recognition commences when the customer receives access to the services and is recognized ratably over the subscription period.

Other revenue consists of fees earned from the temporary staffing and permanent placement of healthcare professionals. Revenue is recognized when control of these services is transferred to the Company's customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services.

***Revenue Disaggregation***

Revenue consisted of the following (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Six Months Ended September 30,** | **Six Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Subscription | $159468 | $129639 | $297344 | $249607 |
| Other | 9057 | 7193 | 17094 | 13901 |
| Total revenue | $168525 | $136832 | $314438 | $263508 |

---

***Contract Balances***

Timing of revenue recognition may differ from the timing of invoicing to customers. Marketing Solutions customers are generally billed for a portion of the contract upon contract execution and then billed throughout the remainder of the contract based on various time-based milestones, starting when the tailored content is first shared on the Doximity platform. Hiring and Workflow Solutions contracts are billed in annual, quarterly, or monthly installments in advance of the service period. The Company's contracts do not contain significant financing components.

The Company records unbilled revenue when revenue is recognized in amounts for which it is contractually entitled but exceeds the amounts the Company has a right to bill as of the end of the period. The Company records unbilled revenue on the condensed consolidated balance sheets within prepaid expenses and other current assets. The Company's unbilled revenue balances were $5.5 million and $1.7 million as of September 30, 2025 and March 31, 2025, respectively.

Deferred revenue consists of noncancelable customer billings or payments received in advance of revenue recognition. Deferred revenue balances are generally expected to be recognized within 12 months. Since the majority of the Company's contracts have a duration of one year or less, the Company has elected not to disclose remaining performance obligations in accordance with the optional exemption in ASC 606. Remaining performance obligations for contracts with an original duration greater than one year are not material.

Revenue recognized from amounts included in deferred revenue as of the beginning of the period was $87.7 million and $76.0 million, for the three months ended September 30, 2025 and 2024, respectively, and $102.9 million and $89.9 million for the six months ended September 30, 2025 and 2024, respectively.

***Deferred Contract Costs***

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)** 

The Company capitalizes sales compensation that is considered to be an incremental and recoverable cost of obtaining a contract with a customer. The Company pays commissions based on signing new arrangements with customers and upon renewals and expansion of existing contracts with customers.

Deferred compensation is generally amortized over the weighted-average contractual term, ranging from 8 months to 14 months. The portion of deferred compensation expected to be recognized within one year of the balance sheet date is included in prepaid expenses and other current assets, and the remaining portion is recorded as other assets on the condensed consolidated balance sheets. The amortization of deferred contract costs is included in sales and marketing expense in the condensed consolidated statements of operations. Sales compensation that is not considered an incremental cost is expensed in the same period that it was earned.

The Company capitalized contract acquisition costs of $2.6 million and $4.6 million for the three and six months ended September 30, 2025, respectively, and $1.8 million and $3.2 million for the three and six months ended September 30, 2024. Amortization of deferred contract costs was $2.9 million and $6.8 million for the three and six months ended September 30, 2025, respectively, and $2.1 million and $4.8 million for the three and six months ended September 30, 2024. The Company's current and non-current deferred contract cost balances were $4.8 million and $0.5 million, respectively, as of September 30, 2025, and were $7.0 million and $0.5 million, respectively, as of March 31, 2025.

Deferred contract costs are periodically analyzed for impairment. There were no impairment losses relating to deferred contract costs during the three and six months ended September 30, 2025 and 2024.

**4. Investments**

The cost, gross unrealized gains and losses, and fair value of investments are as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **As of September 30, 2025** | **As of September 30, 2025** | **As of September 30, 2025** | **As of September 30, 2025** |
| | **Cost or<br>Amortized<br>Cost** | **Gross<br>Unrealized<br>Gains** | **Gross<br>Unrealized<br>Losses** | **Fair Value** |
| Cash equivalents: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Commercial paper | $34977 | $— | $(4) | $34973 |
| &nbsp;&nbsp;&nbsp;&nbsp;Money market funds | 92194 |  |  | 92194 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cash equivalents | 127171 |  | (4) | 127167 |
| Marketable securities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Commercial paper | 30587 | 4 | (1) | 30590 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate notes and bonds | 515522 | 1442 | (46) | 516918 |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. government and agency securities | 161032 | 583 | (5) | 161610 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total marketable securities | 707141 | 2029 | (52) | 709118 |
| Total cash equivalents and marketable securities | $834312 | $2029 | $(56) | $836285 |

---

As of September 30, 2025, the contractual maturities of the Company's available-for-sale debt securities were as follows (in thousands):

---

| | |
|:---|:---|
| | **Fair Value** |
| Due within one year | $491548 |
| Due in one to two years | 252543 |
| Total | $744091 |

---

Actual maturities may differ from contractual maturities because certain borrowers have the right to call or prepay certain obligations.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)** 

The cost, gross unrealized gains and losses, and fair value of investments were as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **As of March 31, 2025** | **As of March 31, 2025** | **As of March 31, 2025** | **As of March 31, 2025** |
| | **Cost or<br>Amortized<br>Cost** | **Gross<br>Unrealized<br>Gains** | **Gross<br>Unrealized<br>Losses** | **Fair Value** |
| Cash equivalents: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Commercial paper | $73055 | $— | $(8) | $73047 |
| &nbsp;&nbsp;&nbsp;&nbsp;Money market funds | 84475 |  |  | 84475 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cash equivalents | 157530 |  | (8) | 157522 |
| Marketable securities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Commercial paper | 42860 | 7 | (4) | 42863 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate notes and bonds | 501202 | 1373 | (131) | 502444 |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. government and agency securities | 160212 | 532 | (1) | 160743 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total marketable securities | 704274 | 1912 | (136) | 706050 |
| Total cash equivalents and marketable securities | $861804 | $1912 | $(144) | $863572 |

---

As of September 30, 2025 and March 31, 2025, the Company has recognized accrued interest of $5.8 million and $5.8 million, respectively, which is included in prepaid expenses and other current assets in the condensed consolidated balance sheets.

The unrealized losses associated with the Company's debt securities were immaterial as of September 30, 2025 and March 31, 2025. As the Company does not intend to sell the securities with unrealized losses and it is more likely than not that the Company will hold these securities until maturity or until the cost basis is recovered, the Company did not recognize any impairment on these securities as of September 30, 2025 or March 31, 2025. The Company did not recognize any credit losses related to the Company's debt securities as of September 30, 2025 or March 31, 2025. The fair value related to the debt securities with unrealized losses for which no credit losses were recognized was $115.2 million and $177.3 million as of September 30, 2025 and March 31, 2025, respectively.

**5. Fair Value Measurements**

Available-for-sale debt securities are recorded at fair value on the condensed consolidated balance sheets. The carrying value of cash equivalents, accounts receivable, accounts payable, and accrued expenses and other current liabilities approximate their respective fair values due to their short maturities.

Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The Company uses a three-tier hierarchy, which prioritizes the inputs used in measuring fair value as follows:

**Level 1**—Inputs that are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.

**Level 2**—Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument's anticipated life.

**Level 3**—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and which reflect management's best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)** 

The following tables present the fair value hierarchy for the Company's assets and liabilities measured at fair value on a recurring basis (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **As of September 30, 2025** | **As of September 30, 2025** | **As of September 30, 2025** | **As of September 30, 2025** |
| | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Cash equivalents: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Commercial paper | $— | $34973 | $— | $34973 |
| &nbsp;&nbsp;&nbsp;&nbsp;Money market funds | 92194 |  |  | 92194 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cash equivalents | 92194 | 34973 |  | 127167 |
| Marketable securities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Commercial paper |  | 30590 |  | 30590 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate notes and bonds |  | 516918 |  | 516918 |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. government and agency securities | 158598 | 3012 |  | 161610 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total marketable securities | 158598 | 550520 |  | 709118 |
| Total cash equivalents and marketable securities | $250792 | $585493 | $— | $836285 |
| Liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Contingent earn-out consideration liability | $— | $— | $5752 | $5752 |
| Total contingent earn-out consideration liability | $— | $— | $5752 | $5752 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **As of March 31, 2025** | **As of March 31, 2025** | **As of March 31, 2025** | **As of March 31, 2025** |
| | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Cash equivalents: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Commercial paper | $— | $73047 | $— | $73047 |
| &nbsp;&nbsp;&nbsp;&nbsp;Money market funds | 84475 |  |  | 84475 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cash equivalents | 84475 | 73047 |  | 157522 |
| Marketable securities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Commercial paper |  | 42863 |  | 42863 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate notes and bonds |  | 502444 |  | 502444 |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. government and agency securities | 157727 | 3016 |  | 160743 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total marketable securities | 157727 | 548323 |  | 706050 |
| Total cash equivalents and marketable securities | $242202 | $621370 | $— | $863572 |
| Liabilities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Contingent earn-out consideration liability | $— | $— | $11493 | $11493 |
| Total contingent earn-out consideration liability | $— | $— | $11493 | $11493 |

---

During the six months ended September 30, 2025 and 2024, the Company had no transfers between levels of the fair value hierarchy.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)** 

***Contingent Earn-out Consideration Liability***

The following table summarizes the changes in the contingent earn-out consideration liability (in thousands):

---

| | | |
|:---|:---|:---|
| | **Six Months Ended September 30,** | **Six Months Ended September 30,** |
| | **2025** | **2024** |
| Beginning fair value | $11493 | $16813 |
| Additions in the period |  |  |
| Change in fair value | 259 | 423 |
| Payments | (6000) | (6000) |
| Ending fair value | $5752 | $11236 |

---

The contingent earn-out consideration liability relates to the AMiON acquisition, which closed on April 1, 2022. The fair value of the liability is remeasured at each reporting date until the related contingency is resolved, with any changes to the fair value recognized as sales and marketing expense in the condensed consolidated statements of operations.

To determine the fair value of the contingent earn-out consideration liability, the Company used the discounted cash flow method. The significant inputs used in the fair value measurement of the contingent earn-out consideration liability are the discount rate and the timing and amounts of the future payments, which are based upon estimates of future achievement of the performance metrics. As these inputs are not based on observable market data, they represent a Level 3 measurement within the fair value hierarchy. Changes in the significant inputs used would significantly impact the fair value of the contingent earn-out consideration liability.

**6. Property and Equipment, Net**

Property and equipment, net consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **March 31, 2025** |
| Furniture and equipment | $1977 | $2140 |
| Computers and software | 505 | 689 |
| Leasehold improvements | 816 | 816 |
| Internal-use software development costs | 40196 | 34958 |
| Total property and equipment | 43494 | 38603 |
| Less: accumulated depreciation and amortization | (27782) | (24947) |
| Total property and equipment, net | $15712 | $13656 |

---

Depreciation and amortization expense on property and equipment was $1.9 million and $3.7 million for the three and six months ended September 30, 2025, respectively, and $1.6 million and $3.1 million for the three and six months ended September 30, 2024, respectively. Included in these amounts was amortization expense for internal-use software development costs of $1.7 million and $3.4 million for the three and six months ended September 30, 2025, respectively, and $1.4 million and $2.7 million for the three and six months ended September 30, 2024, respectively. The amortization of the internal-use software development costs is included in cost of revenue in the condensed consolidated statements of operations.

The Company capitalized internal-use software development costs of $3.4 million and $5.9 million, respectively, during the three and six months ended September 30, 2025, and $2.0 million and $4.0 million, respectively, during the three and six months ended September 30, 2024. Internal-use software development costs are included in property and equipment, net in the condensed consolidated balance sheets.

During the three and six months ended September 30, 2024, an immaterial impairment charge was recognized on property and equipment in connection with a sublease. See Note 12—Impairment Charge for further details. No impairment was recognized on property and equipment during the three and six months ended September 30, 2025.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)** 

**7. Accrued Expenses and Other Current Liabilities**

Accrued expenses and other current liabilities consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **March 31, 2025** |
| Accrued commissions | $4808 | $7053 |
| Accrued payroll, bonus, and related expenses | 9734 | 10761 |
| Employee contributions under employee stock purchase plan | 659 | 587 |
| Rebate liabilities | 2684 | 7172 |
| Sales and other tax liabilities | 1782 | 1357 |
| Current portion of contingent earn-out consideration liability | 5752 | 5914 |
| Other | 8303 | 5561 |
| Total accrued expenses and other current liabilities | $33722 | $38405 |

---

**8. Business Combinations**

***Pathway Acquisition***

On July 29, 2025, the Company completed the acquisition of all outstanding shares of Pathway Medical Inc. ("the Pathway acquisition"), an AI-based medical knowledge platform, primarily to enhance our platform with the acquired technology and engineering workforce. The acquisition-date fair value of the consideration was $36.3 million. This included cash consideration of $26.7 million. Additionally, the Company granted certain Pathway employees joining the Company $23.9 million of restricted stock units ("RSUs"), which vest quarterly over 5 years. A portion of these RSUs with an estimated fair value of $9.6 million, which vest up to the second anniversary of the acquisition date, are guaranteed and not contingent on future events or activities, and, as a result, the related cost is included in the total purchase consideration. The remaining tranches are subject to continuing service with the Company. The related expense is accounted for as post-acquisition stock-based compensation expense.

In connection with the acquisition, the Company granted $4 million of performance-based restricted stock units ("PSUs") and $1 million of RSUs to certain Pathway employees joining the Company. The PSUs will vest in full on November 15, 2026, subject to both service and performance-based vesting conditions. The aggregate grant date fair value of these awards is accounted for as post-acquisition stock-based compensation expense on a straight-line basis, to the extent the performance metrics are achieved. The RSUs vest quarterly over 4 years, the related expense of which is also accounted for as post-acquisition stock-based compensation expense on a straight-line basis.

The Company also committed to issue an additional $8 million of PSUs over the next two fiscal years, beginning in fiscal 2027. The performance targets will be established in the beginning of each fiscal year. These awards are subject to both service and performance-based vesting conditions. As of September 30, 2025, these PSUs are not considered granted from an accounting perspective as the performance targets have not been established.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)** 

The Pathway acquisition was accounted for as a business combination. The purchase consideration was allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date, with the excess recorded to goodwill as shown below. The purchase consideration allocation was as follows (in thousands):

---

| | |
|:---|:---|
| Assets acquired: |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash | $196 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | 148 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | 494 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred taxes | 94 |
| &nbsp;&nbsp;&nbsp;&nbsp;Developed technology | 18700 |
| Total assets acquired | $19632 |
| Liabilities assumed: |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | $391 |
| Net assets acquired, excluding goodwill | 19241 |
| Goodwill | $17033 |
| Total purchase consideration | $36274 |

---

Goodwill generated from the Pathway acquisition represents the future benefits from the developed technology and the assembled workforce. Goodwill from this business combination is deductible for income tax purposes.

Intangible assets acquired are comprised of Pathway's developed technology with an estimated useful life of 5 years. The developed technology was valued using a replacement cost approach, which is based on the cost of a market participant to reconstruct a substitute asset of comparable utility. The results of operations of this business combination have been included in the consolidated financial statements from the acquisition date.

The acquisition-related costs were not material and were recorded as general and administrative expense in the consolidated statements of operations.

Separate operating results and pro forma results of operations for Pathway have not been presented as the effect of this acquisition was not material to the Company's financial results.

**9. Intangible Assets and Goodwill**

***Intangible Assets***

Intangible assets, net consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **March 31, 2025** |
| Customer relationships | $37069 | $37069 |
| Developed technology | 18700 |  |
| Other intangibles | 1531 | 1531 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total intangible assets | 57300 | 38600 |
| Less: accumulated amortization | (18157) | (15528) |
| Total intangible assets, net | $39143 | $23072 |

---

Amortization expense for intangible assets was $1.6 million and $1.0 million for the three months ended September 30, 2025 and 2024, respectively, and $2.6 million and $2.1 million for the six months ended September 30, 2025 and 2024, respectively.

No impairment charges on intangible assets were recorded during the three and six months ended September 30, 2025 and 2024.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)** 

As of September 30, 2025, future amortization expense is as follows (in thousands):

---

| | |
|:---|:---|
| **Year Ending March 31,** | **Amount** |
| Remainder of 2026 | $3876 |
| 2027 | 7750 |
| 2028 | 7750 |
| 2029 | 7750 |
| 2030 | 7750 |
| Thereafter | 4267 |
| Total future amortization expense | $39143 |

---

***Goodwill***

The changes in the carrying amount of goodwill were as follows (in thousands):

---

| | |
|:---|:---|
| | **Six Months Ended September 30, 2025** |
| Balance, beginning of period | $67940 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill acquired | 17033 |
| Balance, end of period | $84973 |

---

No impairment charges on goodwill were recorded during the three and six months ended September 30, 2025 and 2024.

**10. Equity**

***Preferred Stock***

In connection with the IPO, the Company's amended and restated certificate of incorporation became effective, which authorized the issuance of 100,000,000 shares of undesignated preferred stock with a par value of $0.001 per share with rights and preferences, including voting rights, designated from time to time by the board of directors. As of September 30, 2025 and March 31, 2025, there were no shares of preferred stock issued and outstanding.

***Common Stock and Dual-Class Structure***

The Company has two classes of common stock authorized: Class A common stock and Class B common stock, and are collectively referred to as common stock throughout the notes to the condensed consolidated financial statements, unless otherwise noted. The Company's amended and restated certificate of incorporation authorized the issuance of 1,000,000,000 shares of Class A common stock with par value of $0.001 and one vote per share, and 500,000,000 shares of Class B common stock with par value of $0.001 and ten votes per share. The holders of common stock are entitled to receive dividends, as may be declared by the board of directors. Each outstanding share of Class B common stock may be converted at any time at the option of the holder into one share of Class A common stock. As of September 30, 2025, there were 137,192,232 shares of Class A common stock, and 50,897,811 shares of Class B common stock outstanding.

***Stock Repurchase Program***

On May 1, 2024 the Company's board of directors authorized a program to repurchase up to $500 million of the Company's Class A common stock with no expiration date. As of September 30, 2025, the Company repurchased and retired 4,496,467 shares of Class A common stock under this program for an aggregate purchase price of $220.2 million and $279.8 million remained available and authorized for repurchase.

All repurchases are subject to general business and market conditions and other investment opportunities and may be executed through open market purchases or privately negotiated transactions, including through Rule 10b5-1 plans. Immediately upon the repurchase of any shares of Class A common stock, such shares shall be retired by the Company and shall automatically return to the status of authorized but unissued shares of Class A common stock.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)** 

Effective January 1, 2023, the Company's share repurchases in excess of allowable share issuances are subject to a 1% excise tax as a result of the Inflation Reduction Act of 2022. As of September 30, 2025, the Company had accrued excise taxes of $0.3 million and nil as of March 31, 2025.

***Common Stock Warrants***

In October 2021, the Company issued a warrant to U.S. News (the "U.S. News Warrant") to purchase 516,000 shares of Class A common stock with an exercise price of $12.56 per share in connection with the execution of a commercial agreement with U.S. News. The U.S. News Warrant expires 10 years from the date of grant. The first tranche of the U.S. News Warrant vested on May 1, 2022 and the remainder will vest on a monthly basis over approximately 6 years. The grant-date fair value of the U.S. News Warrant was $34.7 million, which was determined using the Black-Scholes option-pricing model on the date of grant. The fair value of the warrant is recognized as expense in cost of revenue in the condensed consolidated statements of operations on a straight-line basis over its vesting term of 6.48 years. During the six months ended September 30, 2025 and 2024, $2.7 million was recognized as stock-based compensation expense relating to the U.S. News Warrant. As of March 31, 2025, 279,500 shares under the warrant were outstanding. During the six months ended September 30, 2025, 50,167 shares with an intrinsic value of $2.3 million were exercised under the warrant and 229,333 shares under the warrant were outstanding as of September 30, 2025. As of September 30, 2025, unamortized stock-based compensation expense related to the unvested warrants was $13.4 million, which is expected to be recognized over the remaining vesting period of 2.50 years.

***Equity Incentive Plans***

The Company maintains three equity incentive plans: the 2010 Equity Incentive Plan (the "2010 Plan"), the 2021 Stock Option and Incentive Plan (the "2021 Plan"), and the 2021 Employee Stock Purchase Plan (the "ESPP"). In June 2021, the Company's board of directors approved the adoption of the 2021 Plan, which became effective upon the Company's initial public offering and supersedes the 2010 Plan. The 2010 Plan continues to govern the terms of outstanding awards that were granted prior to the termination of the 2010 Plan. The 2021 Plan provides for the granting of incentive stock options, nonstatutory stock options, restricted stock units, and restricted stock awards to employees, non-employee directors, and consultants of the Company.

The Company granted stock options under the terms of the Plans and outside of the Plans, as approved by the board of directors. During fiscal 2018, the Company granted 4,682,582 options outside of the Plans, of which 2,114,582 options were exercised and 2,568,000 were outstanding as of September 30, 2025.

The Company has shares of common stock reserved for issuance as follows (in thousands):

---

| | |
|:---|:---|
| | **September 30, 2025** |
| Common stock warrants | 229 |
| 2010 Plan |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options outstanding | 9315 |
| 2021 Plan |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Awards outstanding | 4658 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares available for future grant | 43634 |
| 2021 ESPP | 11598 |
| Options outstanding outside the Plans | 2568 |
| Total | 72002 |

---

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)** 

***Stock Options***

Stock options granted generally vest over four years with service-based, performance-based, and/or market-based conditions and expire ten years from the date of grant.

Stock option activities within the Plans as well as outside of the Plans were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Number of Shares**<br>**(in thousands)** | **Weighted-Average** <br>**Exercise Price** | **Average Remaining Contractual Term** <br>**(in years)** | **Aggregate Intrinsic Value**<br>**(in thousands)** |
| Balance, March 31, 2025 | 13013 | $4.82 | 4.92 | $692422 |
| &nbsp;&nbsp;&nbsp;&nbsp;Options exercised | (1031) | 4.07 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Options forfeited or expired | (99) | 6.71 |  |  |
| Balance, September 30, 2025 | 11883 | 4.87 | 4.40 | 811385 |
| Vested and exercisable as of September 30, 2025 | 9809 | 4.24 | 4.20 | 675959 |
| Vested and expected to vest as of September 30, 2025 | 11883 | 4.87 | 4.40 | 811385 |

---

The aggregate intrinsic value of options exercised during the six months ended September 30, 2025 and 2024 was $57.4 million and $55.1 million, respectively.

As of September 30, 2025, unamortized stock-based compensation expense related to unvested stock options was $7.3 million, which is expected to be recognized over a weighted-average period of 1.65 years.

The Company has not granted any stock options since the first quarter of fiscal 2022.

***Restricted Stock Units ("RSUs")***

The RSUs granted by the Company generally vest over two to four years based on continued service.

The following table summarizes RSU activity (in thousands, except per share information):

---

| | | |
|:---|:---|:---|
| | **Number of Shares** | **Weighted-**<br>**Average**<br>**Grant Date Fair Value** |
| Unvested balance, March 31, 2025 | 3347 | $31.66 |
| &nbsp;&nbsp;&nbsp;&nbsp;Granted | 1570 | 60.13 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vested | (1031) | 35.73 |
| &nbsp;&nbsp;&nbsp;&nbsp;Forfeited | (242) | 34.65 |
| Unvested balance, September 30, 2025 | 3644 | 42.58 |

---

The total fair value of RSUs vested during the six months ended September 30, 2025 and 2024 was $62.0 million and $21.9 million, respectively.

As of September 30, 2025, total unrecognized stock-based compensation expense related to unvested RSUs was $135.3 million, which is expected to be recognized over a weighted-average period of 2.15 years.

***Performance-Based Restricted Stock Units ("PSUs")***

The Company grants PSUs that are subject to both service-based and performance-based vesting conditions that are satisfied upon meeting certain financial performance targets. Certain awards are granted with performance targets to be established in future years. For purposes of the PSUs, grant date cannot occur until performance targets have been clearly established and communicated.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)** 

Additionally, for certain awards, participants can earn up to 200% of the target number of shares originally granted. When achievement exceeds 100%, additional shares will be earned when the achievement is affirmed.

As of March 31, 2025, 480,030 PSUs were outstanding. During the six months ended September 30, 2025, 685,500 PSUs were granted, 89,638 PSUs vested, and 61,578 PSUs were forfeited. As of September 30, 2025, 1,014,314 PSUs were outstanding, of which, 866,030 PSUs are considered granted from an accounting perspective as the performance targets have been established.

As of September 30, 2025, the unamortized stock-based compensation expense related to outstanding PSUs for which performance conditions have been established was $28.0 million, which is calculated based on the probable outcome of the performance conditions as of September 30, 2025. The amount of expense to be recognized will be based on the extent the performance metrics are achieved.

In July 2025, the Compensation Committee of the Board of Directors approved an equity award pool of $30 million, subject to both performance-based and service-based vesting conditions. Participants can earn up to 300% of the original pool. Out of the pool, $23 million worth of PSUs have been granted. As of September 30, 2025, we believe 100% achievement is probable. During the six months ended September 30, 2025, $2.3 million was recognized as stock-based compensation expense, net of amount capitalized as internal use software. As the monetary value of the obligation is based on a fixed monetary amount and will be settled in a variable number of shares, the obligation is recorded as a liability in other liabilities, non-current, on the condensed consolidated balance sheets. Subject to actual achievement, the number of shares will become fixed in the fourth quarter of fiscal 2026, at which point the liability will be reclassified to equity. The individual awards will vest on a quarterly basis through the fourth quarter of fiscal 2027.

***Stock-Based Compensation Expense***

Total stock-based compensation expense recognized in the condensed consolidated statements of operations was as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Six Months Ended September 30,** | **Six Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Cost of revenue | $2844 | $2661 | $5824 | $5555 |
| Research and development | 9862 | 5447 | 16511 | 10131 |
| Sales and marketing | 10508 | 6808 | 18218 | 13394 |
| General and administrative | 6260 | 2952 | 10786 | 5878 |
| Total stock-based compensation expense | $29474 | $17868 | $51339 | $34958 |

---

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)** 

**11. Net Income Per Share Attributable to Common Stockholders**

The following table presents the reconciliation of the numerator and denominator for calculating basic and diluted net income per share (in thousands, except per share data):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Six Months Ended September 30,** | **Six Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Numerator**  |  |  |  |  |
| Net income | $62059 | $44154 | $115379 | $85531 |
| **Denominator**  |  |  |  |  |
| Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders, basic | 187705 | 186252 | 187844 | 185933 |
| Dilutive effect of stock options | 11166 | 13162 | 11308 | 13230 |
| Dilutive effect of other share-based awards | 1874 | 993 | 1800 | 655 |
| Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders, diluted | 200745 | 200407 | 200952 | 199818 |
| Net income per share attributable to Class A and Class B common stockholders:  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.33 | $0.24 | $0.61 | $0.46 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.31 | $0.22 | $0.57 | $0.43 |

---

Certain potentially dilutive securities have been excluded from the calculation of diluted net income per share during the applicable periods because their inclusion would have been anti-dilutive (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Six Months Ended September 30,** | **Six Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Other share-based awards | 30 | 271 | 160 | 626 |
| Common stock warrants | 237 | 405 | 249 | 460 |
| Total | 267 | 676 | 409 | 1086 |

---

**12. Impairment Charge**

During the three months ended September 30, 2024, the Company executed a sublease for a portion of its Curative office space in Irving, Texas. The Company evaluated the associated asset group for impairment, which included the right-of-use assets and underlying property and equipment for the lease. The Company compared the expected future undiscounted cash flows to the carrying value and determined the respective asset group was not fully recoverable. The Company calculated the fair value based on the present value of the estimated cash flows from the sublease for the remaining lease term and compared the estimated fair value to its carrying value, which resulted in a $2.3 million impairment charge. The fair value of the operating lease right-of-use assets and associated property and equipment was estimated as of the sublease execution date using level 3 inputs based on an income approach by converting future sublease cash inflows and outflows to a single present value. Estimated cash flows were discounted at a rate commensurate with the inherent risks associated with the asset group to arrive at an estimate of fair value. The impairment charge was included in restructuring and impairment charge in the consolidated statements of operations. No impairment was recognized during the three and six months ended September 30, 2025.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)** 

**13. Commitments and Contingencies**

***Contractual Commitments***

The Company has contractual commitments that relate mainly to third-party cloud infrastructure agreements and subscription agreements, which are used to facilitate the Company's operations.

The Company has a web hosting arrangement for 3 years ending December 31, 2027, with an annual commitment of $7 million. As of September 30, 2025, the total remaining commitment was $14 million.

***Indemnification***

The Company enters into indemnification provisions under agreements with other companies in the ordinary course of business, including, but not limited to, clients, business partners, landlords, and other parties involved in the performance of the Company's services. Pursuant to these arrangements, the Company has agreed to indemnify, hold harmless, and reimburse the indemnified party for certain losses suffered or incurred by the indemnified party as a result of the Company's activities. The terms of these indemnification agreements are generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable. The Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification agreements. The Company maintains commercial general liability insurance and product liability insurance that may offset certain of its potential liabilities under these indemnification provisions.

In addition, the Company has agreed to indemnify its officers and directors and certain key employees while they are serving in good faith in their respective capacities. To date, there have been no material claims under these indemnification provisions.

***Legal Matters***

Beginning in April 2024, the Company and certain of our directors and officers have been named in lawsuits in the United States District Court for the Northern District of California. The first lawsuit is captioned In re Doximity, Inc. Securities Litigation, No. 5:24-cv-02281 (N.D. Cal.). The operative complaint brings securities law claims on behalf of a putative class of our investors from June 24, 2021 and August 8, 2023 against the Company and our CEO related to our disclosure of user count and engagement rates. Five shareholder derivative lawsuits have also been filed. Two are consolidated under the caption In re Doximity, Inc. Stockholder Derivative Litigation, No. 5:24-cv-02801 (N.D. Cal.). Two were filed in the United States District Court for the District of Delaware, they are captioned Guttman v. Tangney, et al,. 1:24-cv-01387 (D. Del) and Wong v. Tangney, et al., No. 1:25-cv-750 (D. Del.). One was filed in the Court of Chancery of the State of Delaware with the caption, Stern v. Tangney, et al., No. 2025-0661 (Del. Ch.) The complaints assert claims for, among other things, violations of securities law, breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste against certain of our directors and officers on a similar basis to the securities lawsuit. The securities lawsuit is currently proceeding in the discovery phase. Other similar lawsuits or proceedings may be initiated in the future. The defendants intend to defend vigorously against these actions. In light of, among other things, the early stage of the litigation, the Company is unable to predict the outcome of these matters and is unable to reasonably estimate the amount or range of loss, if any, that could result from an unfavorable outcome.

On June 20, 2025, the Company, its Chief Technology Officer and its Director of AI Products were named as defendants in a lawsuit in the U.S. District Court for the District of Massachusetts, captioned OpenEvidence Inc. v. Doximity, Inc. et al., No. 1:25-cv-11802-RGS (D. Mass.). On September 17, 2025, the defendants filed their Answer and Counterclaims, in which they asserted counterclaims against the plaintiff including false advertising in violation of the Lanham Act, the Massachusetts Consumer Protection Law, and common law defamation. On October 29, 2025, the plaintiff amended its Complaint, adding Doximity's subsidiary Pathway Medical, Inc. and certain other individuals as defendants. In its Amended Complaint, the plaintiff alleges the defendants gained unauthorized access to and launched cyberattacks against the defendant's AI medical information platform. The Amended Complaint asserts claims for violation of the Computer Fraud and Abuse Act (CFAA), breach of contract, unjust enrichment, and trespass to chattels. The Amended Complaint dropped several previously asserted claims against the defendants, including a trade secrets claim under the Defend Trade Secrets Act (DTSA). The Amended Complaint requests a permanent injunction enjoining defendants from (i) accessing plaintiff's platform; and (ii) engaging in any further conduct that violates plaintiff's rights; an order to return or destroy the plaintiff's information; actual damages, including lost profits; defendants' profits and unjust enrichment attributable to the alleged misconduct; among other remedies. The

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)** 

defendants intend to defend vigorously against these claims. In light of, among other things, the early stage of the litigation, the Company is unable to predict the outcome of these matters and is unable to reasonably estimate the amount or range of loss, if any, that could result from an unfavorable outcome.

From time to time, the Company has become involved in claims and other legal matters arising in the ordinary course of business. The Company investigates these claims as they arise. Although claims are inherently unpredictable, the Company is currently not aware of any other matters that, if determined adversely to the Company, would individually or taken together have a material effect on its results of operations, financial position, or cash flows. No material loss contingencies were recorded for the three and six months ended September 30, 2025 and 2024.

**14. Leases**

The Company has non-cancelable operating leases for the rental of office space with various expiration dates through 2030.

The components of lease expense were as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Six Months Ended September 30,** | **Six Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Operating lease cost, net of sublease income | $468 | $615 | $938 | $1246 |
| Variable lease cost | 14 | 3 | 29 | 9 |
| Total lease cost | $482 | $618 | $967 | $1255 |

---

During the three months ended September 30, 2024, the Company executed a sublease for a portion of its Curative office space in Irving, Texas. Any impairment to the associated right-of-use assets and underlying property and equipment as a result of a sublease is recognized in the period the sublease is executed and recorded in the condensed consolidated statements of operations. See Note 12 for further details.

The sublease commenced in November 2024 and has a lease term of approximately 5.5 years. The Company has classified the sublease as an operating lease. Total lease payments under the sublease are $2.4 million over the lease term of the sublease. Sublease income is recognized as a reduction of lease expense in the Company's consolidated statements of operations. No sublease income was recognized for the three and six months ended September 30, 2024.

Supplemental cash flow information related to leases was as follows (in thousands):

---

| | | |
|:---|:---|:---|
| | **Six Months Ended September 30,** | **Six Months Ended September 30,** |
| | **2025** | **2024** |
| Cash paid for amounts included in measurement of lease liabilities—Operating cash flows | $1377 | $1350 |

---

Supplemental balance sheet information related to leases was as follows:

---

| | | |
|:---|:---|:---|
| | **September 30, 2025** | **March 31, 2025** |
| Weighted-average remaining lease term (in years) | 4.72 | 5.17 |
| Weighted-average discount rate | 4.19% | 4.19% |

---

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)** 

Maturities of operating lease liabilities, excluding sublease income, as of September 30, 2025 were as follows (in thousands):

---

| | |
|:---|:---|
| Remainder of 2026 | $1310 |
| 2027 | 2497 |
| 2028 | 2605 |
| 2029 | 2667 |
| 2030 | 2706 |
| Thereafter | 679 |
| Total future lease payments | $12464 |
| Less: imputed interest | (1195) |
| Present value of lease liabilities | $11269 |

---

**15. Other Income, net**

Other income, net consisted of the following (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Six Months Ended September 30,** | **Six Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Interest income | $9436 | $9112 | $19301 | $16280 |
| Net gain on sale of marketable securities |  | 31 |  | 31 |
| Other expense | (178) | (114) | (413) | (166) |
| Other income, net | $9258 | $9029 | $18888 | $16145 |

---

**16. Income Taxes**

The Company's tax provision for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items, if any. The Company's effective tax rates for the three and six months ended September 30, 2025 were 14.9% and 15.8%, respectively, and 29.0% and 25.8% for the three and six months ended September 30, 2024, respectively.

The Company's effective tax rate differs from the U.S. federal statutory rate, primarily due to stock-based compensation related tax benefits, which are subject to limitations for certain executive officers under IRC section 162(m), and federal and state research and development tax credits. The Company's effective tax rate is based on forecasted annual income before income taxes which may fluctuate through the rest of the year.

In July 2025, Congress passed and the President signed into law H.R. 1, the One Big Beautiful Bill Act ("Tax Act") which addresses certain business tax provisions enacted as a part of the 2017 Tax Cuts and Jobs Act including restoration of Section 174 expensing for US-based research. Accounting Standards Codification Topic 740, Income Taxes, ("Topic 740") requires the tax impacts to be included in the reporting period that includes the date the Tax Act was signed into law. The impacts of the Tax Act are reflected in our results for the fiscal quarter ended September 30, 2025, and there was no material impact to our income tax expense or effective tax rate. Management elected to accelerate the deduction of all remaining unamortized domestic R&D expenses originally capitalized in fiscal years 2023 through 2025 in one year—i.e., in fiscal year 2026. The net deductions benefit increased the Company's September 30, 2025 prepaid taxes and decreased our deferred tax assets by approximately $40.4 million.

**17. Segment and Geographic Information**

The Company has determined that it has one operating and reportable segment. The Chief Operating Decision Maker ("CODM") is the Company's Chief Executive Officer ("CEO"); he reviews financial information presented on a consolidated basis for purposes of making operating decisions, assessing financial performance, and allocating resources. The Company's operating segment derives revenue in a manner as described in Note 3—Revenue.

The CODM assesses performance for the operating segment and decides how to allocate resources based on the review of consolidated net income, which the CODM uses to monitor budget versus actual results and review historical company

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**DOXIMITY, INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**(unaudited)** 

performance trends. Significant segment expenses were determined to include cost of revenues, research and development expenses, sales and marketing expenses, general and administrative expenses, impairment charge, other income, net, and provision for income taxes, all of which are presented in the condensed consolidated statements of operations for the three and six months ended September 30, 2025 and 2024. Significant segment expenses also include stock-based compensation expense and depreciation and amortization expense, which are presented in Note 10—Equity and the condensed consolidated statements of cash flows, respectively for the three and six months ended September 30, 2025 and 2024. All intercompany transactions are eliminated upon consolidation. Assets provided to the CODM are consistent with those reported on the condensed consolidated balance sheets.

Substantially all of the Company's long-lived assets were based in the United States as of September 30, 2025 and March 31, 2025. For the three and six months ended September 30, 2025 and 2024, no country outside of the United States accounted for more than 10% of total revenue and substantially all of the Company's revenue was derived in the United States.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and accompanying notes that are included elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K, filed with the SEC on May 20, 2025. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties, as described under the heading "Special Note Regarding Forward-Looking Statements" in this Quarterly Report on Form 10-Q. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under the section titled "Risk Factors" in Part 1, Item 1A of our Annual Report on Form 10-K or in other parts of this Quarterly Report on Form 10-Q. Our historical results are not necessarily indicative of the results that may be expected for any period in the future, and our interim results are not necessarily indicative of the results that may be expected for the full fiscal year or any other period. The last day of our fiscal year is March 31*<sup>st</sup>*. Our fiscal quarters end on June 30*<sup>th</sup>*, September 30*<sup>th</sup>*, December 31*<sup>st</sup>*, and March 31*<sup>st</sup>*. Fiscal 2026, our current fiscal year, will end on March 31, 2026.* 

**Overview** 

We are the leading digital platform for U.S. medical professionals, as measured by the number of members. Our members include more than 80% of U.S. physicians, spanning all 50 states and every medical specialty.

Our mission is to help every physician be more productive and provide better care for their patients. We are physicians-first, putting technology to work for doctors instead of the other way around. That guiding principle has enabled Doximity to become an essential and trusted professional platform for physicians and their colleagues. Doximity puts modern software in the hands of physicians and other medical professionals. We provide our members with digital tools specifically built for medicine, enabling our members to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits.

At the core of our platform is the largest medical professional network in the nation, which creates proximity within our community of doctors and other medical professionals. Verified members can search and connect with colleagues and specialists, which allows them to better coordinate patient care and streamline referrals. Our newsfeed addresses the ever increasing sub-specialization of medical expertise and volume of medical research by delivering news and information that is relevant to each physician's clinical practice. We also support physicians in their day-to-day practice of medicine with mobile-friendly and easy-to-use workflow tools such as voice and video dialer, secure messaging, digital faxing, and our AI-powered workflow tools. Our business model is designed to both respect and support physicians while driving value for our customers through our Marketing, Hiring, and Workflow Solutions. Our revenue-generating customers, primarily pharmaceutical manufacturers and health systems, have access to a suite of commercial solutions that benefit from broad physician usage.

Our business model has delivered high revenue growth at scale with profitability. For the three months ended September 30, 2025 and 2024, we recognized revenue of $168.5 million and $136.8 million, respectively, representing a year-over-year growth rate of 23%. For the six months ended September 30, 2025 and 2024, we recognized revenue of $314.4 million and $263.5 million, respectively, representing a year-over-year growth rate of 19%. For the three months ended September 30, 2025 and 2024, our net income was $62.1 million and $44.2 million and our adjusted EBITDA was $100.8 million and $76.1 million, respectively. For the six months ended September 30, 2025 and 2024, our net income was $115.4 million and $85.5 million and our adjusted EBITDA was $180.6 million and $142.1 million, respectively. We have accomplished this while focusing on our core mission to help every physician be more productive and provide better care for their patients.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**Key Business and Financial Metrics**

We monitor a number of key business and financial metrics to assess the health and success of our business, including:

***Customers with Trailing 12-Month Subscription Revenue Greater than $500,000.*** The number of customers with trailing 12-month ("TTM") subscription revenue greater than $500,000 is a key indicator of the scale of our business, and is calculated by counting the number of customers that contributed more than $500,000 in subscription revenue in the TTM period. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity, and we present our total customer count for historical periods reflecting these adjustments.

The number of customers with at least $500,000 of revenue has grown steadily in recent years as we have engaged new customers and expanded within existing ones. This cohort of customers accounted for approximately 84% of our revenue for the TTM ended September 30, 2025.

---

| | | |
|:---|:---|:---|
| | **September 30,** | **September 30,** |
| | **2025** | **2024** |
| Number of customers with at least $500,000 of revenue  | 121 | 104 |

---

***Net Revenue Retention Rate.*** Net revenue retention rate is calculated by taking the TTM subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. For the purposes of this calculation, subscription revenue excludes subscriptions for individuals and small practices and other non-recurring items. Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn. Our net revenue retention rate is directly tied to our revenue growth rate and thus fluctuates as that growth rate fluctuates.

---

| | | |
|:---|:---|:---|
| | **September 30,** | **September 30,** |
| | **2025** | **2024** |
| Net revenue retention rate | 118% | 116% |

---

***Non-GAAP Financial Measures***

We use adjusted EBITDA and free cash flow to measure our performance, identify trends, formulate financial projections, and make strategic decisions.

***Adjusted EBITDA***

We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, impairment charge, legal fees associated with certain non-ordinary course legal matters including the shareholder class action litigation, change in fair value of contingent earn-out consideration liability, and other income, net. Net income margin represents net income as a percentage of revenue and adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.

Adjusted EBITDA is a key measure we use to assess our financial performance and is also used for internal planning and forecasting purposes. We believe adjusted EBITDA is helpful to investors, analysts, and other interested parties because it can assist in providing a more consistent and comparable overview of our operations across our historical financial periods.

Adjusted EBITDA and adjusted EBITDA margin are non-GAAP measures and are presented for supplemental informational purposes only and should not be considered as alternatives or substitutes to the financial information presented in accordance with GAAP. These measures have certain limitations in that they do not include the impact of certain expenses that are reflected in our condensed consolidated statements of operations that are necessary to run our business. Other companies, including other companies in our industry, may not use these measures or may calculate these measures differently than as presented in this Quarterly Report on Form 10-Q, limiting their usefulness as comparative measures.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

The following table presents a reconciliation of net income to adjusted EBITDA, adjusted EBITDA margin, and net income margin (in thousands, except percentages):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Six Months Ended September 30,** | **Six Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Net income | $62059 | $44154 | $115379 | $85531 |
| Adjusted to exclude the following: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisition and other related expenses | 1188 |  | 1616 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 29474 | 17868 | 51339 | 34958 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 3469 | 2613 | 6263 | 5175 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for income taxes | 10880 | 18017 | 21707 | 29809 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment charge |  | 2304 |  | 2304 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of contingent earn-out consideration liability | 91 | 221 | 259 | 423 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal expenses | 2927 |  | 2927 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income, net | (9258) | (9029) | (18888) | (16145) |
| Adjusted EBITDA | $100830 | $76148 | $180602 | $142055 |
| Revenue | $168525 | $136832 | $314438 | $263508 |
| Net income margin | 37% | 32% | 37% | 32% |
| Adjusted EBITDA margin | 60% | 56% | 57% | 54% |

---

***Free Cash Flow***

Free cash flow is a key performance measure that our management uses to assess our overall performance. We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investing in our business, making strategic acquisitions, and strengthening our financial position.

We calculate free cash flow as cash flow from operating activities less purchases of property and equipment and internal-use software development costs.

Although we believe free cash flow is a useful indicator of business performance, free cash flow is presented for supplemental informational purposes only and should not be considered a substitute for financial information presented in accordance with GAAP. Free cash flow has limitations as an analytical tool, and it should not be considered in isolation or as a substitute for analysis of other GAAP financial measures, such as net cash provided by operating activities. Some of the limitations of free cash flow are that it may not properly reflect future contractual commitments that have not been realized in the current period. Our free cash flow may not be comparable to similarly titled measures of other companies because they may not calculate free cash flow in the same manner as we calculate the measure, limiting its usefulness as a comparative measure.

The following table presents a reconciliation of our free cash flow to the most comparable GAAP measure, net cash provided by operating activities, for each of the periods indicated (in thousands):

---

| | | |
|:---|:---|:---|
| | **Six Months Ended September 30,** | **Six Months Ended September 30,** |
| | **2025** | **2024** |
| Net cash provided by operating activities | $156045 | $109589 |
| &nbsp;&nbsp;&nbsp;&nbsp;Internal-use software development costs | (4335) | (3247) |
| Free cash flow | $151710 | $106342 |
| Other cash flow components: |  |  |
| Net cash provided by (used in) investing activities | $(29032) | $54099 |
| Net cash used in financing activities | $(167378) | $(76225) |

---

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**Components of Results of Operations**

***Revenue***

*Marketing Solutions.* Our customers purchase a subscription to Marketing Solutions, either directly or through marketing agencies, for the ability to share tailored content on the Doximity platform via a variety of modules for defined time periods. We generally bill customers a portion of the contract upon contract execution and then bill throughout the remainder of the contract based on various time-based milestones. Generally, we bill in advance of revenue recognition. When revenue is recognized in advance of billings, we record unbilled revenue. Unbilled revenue is recorded on the condensed consolidated balance sheets within prepaid expenses and other current assets. Subscriptions to Marketing Solutions include the following contractual arrangements:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Subscriptions for specific modules delivered on a monthly basis to a consistent number of targeted Doximity members during the subscription period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Integrated and other subscriptions that are not tied to a single module per month but allow customers to utilize a given module or combination of modules during the subscription period, subject to limits on the total number of modules launched in a given period of time, active at any given time, and members targeted.

For these subscription-based contractual arrangements, pricing is based on the number and composition of the targeted Doximity members, and on the specific modules purchased. We recognize revenue over time as control of the service is transferred to the customer.

*Hiring and Workflow Solutions.* We provide Hiring Solutions customers access to our platform which enables them to post job openings or deliver a fixed number of monthly messages to our network of medical professionals. We offer Workflow Solutions customers access to telehealth tools, on-call scheduling, and our AI writing assistant during the subscription period. Hiring and Workflow Solutions contracts are noncancelable and customers are billed in annual, quarterly, or monthly installments in advance of the service period, and revenue is recognized ratably over the contractual term.

We also generate revenue from temporary and permanent medical recruiting services which we charge on an hourly-fee, and retainer and placement-fee basis, respectively. For the three and six months ended September 30, 2025 and 2024, the revenue from temporary and permanent medical recruiting services was not significant to our total revenue.

For a description of our revenue accounting policies, see Note 2—Summary of Significant Accounting Policies included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended March 31, 2025 and filed with the SEC on May 20, 2025.

***Cost of Revenue***

Cost of revenue is primarily comprised of expenses related to cloud hosting, personnel-related expenses for our customer success team, costs for third-party platform access, information technology, software subscription costs, and other services used in connection with the delivery and support of our platform. Our cost of revenue also includes the amortization of internal-use software development costs, editorial and other content-related expenses, and allocated overhead. Cost of revenue is driven by the growth of our member network and utilization of our workflow tools. We intend to continue to invest additional resources in our cloud infrastructure and our customer support organizations to support the growth of our business.

***Gross Profit and Gross Margin***

Gross profit is total revenue less total cost of revenue. Gross margin is gross profit expressed as a percentage of total revenue. Gross profit and gross margin has been and will continue to be affected by a number of factors, including the timing of our acquisition of new customers and sales of additional solutions to existing customers, the timing and extent of our investments in our operations, cloud hosting costs, growth in our customer success team, and the timing of internal-use software development costs amortization. We expect our gross margin to remain relatively steady over the near term, although our quarterly gross margin is expected to fluctuate from period to period depending on the interplay of these and other factors.

***Operating Expenses***

Our operating expenses consist of research and development, sales and marketing, and general and administrative expenses.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

***Research and Development***

Research and development expense is primarily comprised of personnel-related expenses associated with our engineering and product teams who are responsible for building new products and improving existing products. Research and development expense also includes costs for information technology, software-related costs, contractors, third-party services, amortization of acquired intangibles, and allocated overhead. Other than internal-use software development costs that qualify for capitalization, research and development costs are expensed as incurred. We expect research and development expenses will increase on an absolute dollar basis as we continue to grow our platform and product offerings.

***Sales and Marketing***

Sales and marketing expense is primarily comprised of personnel-related expenses, sales incentive compensation, advertising costs, travel, and other event expenses. Sales and marketing expense also includes costs for information technology, software-related costs, contractors, third-party services, allocated overhead, intangible assets amortization, and change in fair value of contingent earn-out consideration liability. We capitalize sales incentive compensation that is considered to be an incremental and recoverable cost of obtaining a contract with a customer. These sales incentive compensation costs are amortized over the period of benefit. We expect sales and marketing expense to increase and to be our largest expense on an absolute basis.

***General and Administrative***

General and administrative expense is primarily comprised of personnel-related expenses associated with our executive, finance, legal, human resources, information technology, and facilities employees. General and administrative expense includes fees for third-party legal and accounting services, insurance expense, information technology, software-related costs, and allocated overhead. We expect that general and administrative expense will increase on an absolute dollar basis as we incur compliance costs associated with being a publicly-traded company, including legal, audit, and consulting fees.

***Impairment Charge***

Impairment charge includes impairment of right-of-use and other property and equipment recognized upon the execution of a sublease for a portion of our office space.

***Other Income, Net***

Other income, net consists primarily of interest income earned on our cash equivalents and marketable securities.

***Provision for Income Taxes***

Provision for income taxes consists primarily of income taxes in U.S. federal, state, and local jurisdictions in which we conduct business. We continue to maintain a valuation allowance related to specific net deferred tax assets where it is not more likely than not that the deferred tax assets will be realized, which includes Arizona research and development credits and capital loss carryforwards. We calculate income taxes in interim periods by applying an estimated annual effective tax rate to income before income taxes and by calculating the tax effect of discrete items recognized during the period. Our effective income tax rate generally differs from the U.S. statutory tax rate of 21.0% primarily due to stock-based compensation related tax benefits, which are subject to limitations for certain executive officers under IRC section 162(m), and federal and state research and development tax credits.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**Results of Operations**

The following tables set forth our condensed consolidated results of operations data and such data as a percentage of revenue for the periods presented.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Six Months Ended September 30,** | **Six Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Revenue | $168525 | $136832 | $314438 | $263508 |
| Cost of revenue<sup>(1)</sup> | 16425 | 13676 | 32218 | 27226 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 152100 | 123156 | 282220 | 236282 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development<sup>(1)</sup> | 30202 | 23240 | 57001 | 45814 |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing<sup>(1)</sup> | 39168 | 34367 | 75533 | 69611 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative<sup>(1)</sup> | 19049 | 10103 | 31488 | 19358 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment charge |  | 2304 |  | 2304 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 88419 | 70014 | 164022 | 137087 |
| Income from operations | 63681 | 53142 | 118198 | 99195 |
| Other income, net | 9258 | 9029 | 18888 | 16145 |
| Income before income taxes | 72939 | 62171 | 137086 | 115340 |
| Provision for income taxes | 10880 | 18017 | 21707 | 29809 |
| Net income | $62059 | $44154 | $115379 | $85531 |

---

_______________

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Costs and expenses include stock-based compensation expense as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Six Months Ended September 30,** | **Six Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| | **(in thousands)** | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| Cost of revenue | $2844 | $2661 | $5824 | $5555 |
| Research and development | 9862 | 5447 | 16511 | 10131 |
| Sales and marketing | 10508 | 6808 | 18218 | 13394 |
| General and administrative | 6260 | 2952 | 10786 | 5878 |
| Total stock-based compensation expense | $29474 | $17868 | $51339 | $34958 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Six Months Ended September 30,** | **Six Months Ended September 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| | **(percentages of revenue)** | **(percentages of revenue)** | **(percentages of revenue)** | **(percentages of revenue)** |
| Revenue | 100% | 100% | 100% | 100% |
| Cost of revenue | 10 | 10 | 10 | 10 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 90 | 90 | 90 | 90 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 18 | 17 | 18 | 17 |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | 23 | 25 | 24 | 27 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 11 | 8 | 10 | 8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment charge |  | 2 |  | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 52 | 52 | 52 | 53 |
| Income from operations | 38 | 38 | 38 | 37 |
| Other income, net | 5 | 7 | 6 | 6 |
| Income before income taxes | 43 | 45 | 44 | 43 |
| Provision for income taxes | 6 | 13 | 7 | 11 |
| Net income | 37% | 32% | 37% | 32% |

---

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

***Comparison of the three and six months ended September 30, 2025 and 2024.***

*Revenue*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Change** | **Six Months Ended September 30,** | **Six Months Ended September 30,** | **Change** |
| | **2025** | **2024** | $**%** | **2025** | **2024** | $**%** |
| | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** |
| Revenue | $168525 | $136832 | 23% | $314438 | $263508 | 19% |

---

Revenue for the three months ended September 30, 2025 increased $31.7 million as compared to the same period in 2024. The increase was primarily driven by a $29.8 million increase in subscription revenue. Of the increase in subscription revenue, $9.3 million was driven by the addition of new subscription customers<sup>1</sup> and $20.5 million was due to the expansion of existing customers. The expansion of existing customers was primarily driven by average revenue per existing Marketing Solutions customers increasing by approximately 20% as a result of adding new and growing existing brands and service lines. Approximately 95% of our revenue for the three months ended September 30, 2025 was derived from subscription customers.

Revenue for the six months ended September 30, 2025 increased $50.9 million as compared to the same period in 2024. The increase was primarily driven by a $47.7 million increase in subscription revenue. Of the increase in subscription revenue, $11.0 million was driven by the addition of new subscription customers<sup>1</sup> and $36.7 million was due to the expansion of existing customers. The expansion of existing customers was primarily driven by average revenue per existing Marketing Solutions customers increasing by approximately 18% as a result of adding new and growing existing brands and service lines. Approximately 95% of our revenue for the six months ended September 30, 2025 was derived from subscription customers.

*Cost of revenue, gross profit and gross margin*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Change** | **Six Months Ended September 30,** | **Six Months Ended September 30,** | **Change** |
| | **2025** | **2024** | $**%** | **2025** | **2024** | $**%** |
| | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** |
| Cost of revenue | $16425 | $13676 | 20% | $32218 | $27226 | 18% |
| Gross profit | $152100 | $123156 | 24% | $282220 | $236282 | 19% |
| Gross margin | 90% | 90% |  | 90% | 90% |  |

---

Cost of revenue for the three and six months ended September 30, 2025 increased $2.7 million and $5.0 million as compared to the same periods in 2024. The increase was primarily driven by increases in personnel, hosting, and other costs to support revenue growth.

The gross margin for the three and six months ended September 30, 2025 remained consistent as compared to the same period in 2024.

***Operating Expenses***

*Research and development* 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Change** | **Six Months Ended September 30,** | **Six Months Ended September 30,** | **Change** |
| | **2025** | **2024** | $**%** | **2025** | **2024** | $**%** |
| | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** |
| Research and development | $30202 | $23240 | 30% | $57001 | $45814 | 24% |

---

Research and development expense for the three months ended September 30, 2025 increased $7.0 million as compared to the same period in 2024. The increase was driven by a $4.4 million increase in stock-based compensation as a result of new awards granted to new hires and existing employees, a $1.4 million increase in third-party contractor costs, and a $1.1 million increase in personnel costs due to merit increases and increases in average headcount.

<sup>1</sup> We define new subscription customers as revenue generating subscription customers in the current fiscal period who did not contribute any revenue for the same period in the prior fiscal year.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

Research and development expense for the six months ended September 30, 2025 increased $11.2 million as compared to the same period in 2024. The increase was driven by a $6.4 million increase in stock-based compensation as a result of new awards granted to new hires and existing employees, a $2.5 million increase in personnel costs due to merit increases and increases in average headcount, and a $2.0 million increase in third-party contractor costs.

*Sales and marketing*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Change** | **Six Months Ended September 30,** | **Six Months Ended September 30,** | **Change** |
| | **2025** | **2024** | $**%** | **2025** | **2024** | $**%** |
| | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** |
| Sales and marketing | $39168 | $34367 | 14% | $75533 | $69611 | 9% |

---

Sales and marketing expense for the three months ended September 30, 2025 increased $4.8 million as compared to the same period in 2024, primarily driven by $3.7 million increase in stock-based compensation as a result of new awards granted to new hires and existing employees, and $1.3 million increase in marketing activities.

Sales and marketing expense for the six months ended September 30, 2025 increased $5.9 million as compared to the same period in 2024, primarily driven by a $4.8 million increase in stock-based compensation as a result of new awards granted to new hires and existing employees, and a $2.0 million increase in marketing activities.

*General and administrative*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Change** | **Six Months Ended September 30,** | **Six Months Ended September 30,** | **Change** |
| | **2025** | **2024** | $**%** | **2025** | **2024** | $**%** |
| | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** |
| General and administrative | $19049 | $10103 | 89% | $31488 | $19358 | 63% |

---

General and administrative expense for the three months ended September 30, 2025 increased $8.9 million as compared to the same period in 2024, primarily driven by $3.9 million increase in legal expenses, $3.3 million increase in stock-based compensation as a result of new awards granted to new hires and existing employees, and a $1.2 million increase related to acquisition expenses.

General and administrative expense for the six months ended September 30, 2025 increased $12.1 million as compared to the same period in 2024, primarily driven by a $4.9 million increase in stock-based compensation as a result of new awards granted to new hires and existing employees, $4.6 million increase in legal and accounting expenses, a $1.6 million increase related to acquisition expenses, and a $0.8 million increase in personnel costs due to merit increases.

*Impairment charge*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Change** | **Six Months Ended September 30,** | **Six Months Ended September 30,** | **Change** |
| | **2025** | **2024** | $**%** | **2025** | **2024** | $**%** |
| | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** |
| Impairment charge | $— | $2304 | NM | $— | $2304 | NM |

---

During the three and six months ended September 30, 2024, the Company executed a sublease for its Curative office space in Irving, Texas, which resulted in a $2.3 million impairment charge for the subleased asset group.

***Other income, net***

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Change** | **Six Months Ended September 30,** | **Six Months Ended September 30,** | **Change** |
| | **2025** | **2024** | $**%** | **2025** | **2024** | $**%** |
| | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** |
| Other income, net | $9258 | $9029 | 3% | $18888 | $16145 | 17% |

---

Other income, net for the three months ended September 30, 2025 remained materially consistent as compared to the same period in 2024.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

Other income, net for the six months ended September 30, 2025 increased $2.7 million as compared to the same period in 2024, primarily driven by increases in interest income due to higher yields earned on our cash equivalents and marketable securities portfolio and a higher average portfolio balance.

***Provision for income taxes***

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Change** | **Six Months Ended September 30,** | **Six Months Ended September 30,** | **Change** |
| | **2025** | **2024** | $**%** | **2025** | **2024** | $**%** |
| | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** | **(in thousands, except percentages)** |
| Provision for income taxes | $10880 | $18017 | (40)% | $21707 | $29809 | (27)% |

---

Income tax expense for the three and six months ended September 30, 2025 decreased $7.1 million and $8.1 million as compared to the same periods in 2024, primarily driven by increased tax deductions from stock award activities offset in part by higher income before taxes.

**Liquidity and Capital Resources**

Since inception, we have financed operations primarily through proceeds received from sales of equity securities and payments received from our customers. As of September 30, 2025, our principal sources of liquidity were cash and cash equivalents and marketable securities of $878.4 million. Our marketable securities consist of U.S. government and agency securities, corporate notes and bonds, and commercial paper.

On May 1, 2024 the Company's board of directors authorized a program to repurchase up to $500 million of the Company's Class A common stock with no expiration date. As of September 30, 2025, the Company repurchased and retired 4,496,467 shares of Class A common stock under this program for an aggregate purchase price of $220.2 million and $279.8 million remained available and authorized for repurchase.

All repurchases are subject to general business and market conditions and other investment opportunities and may be executed through open market purchases or privately negotiated transactions, including through Rule 10b5-1 plans. Immediately upon the repurchase of any shares of Class A common stock, such shares shall be retired by the Company and shall automatically return to the status of authorized but unissued shares of Class A common stock.

Effective January 1, 2023, the Company's share repurchases in excess of allowable share issuances are subject to a 1% excise tax as a result of the Inflation Reduction Act of 2022. As of September 30, 2025, the Company had accrued excise taxes of $0.3 million and nil as of March 31, 2025.

We believe that our existing cash and cash equivalents and marketable securities will be sufficient to support working capital and capital expenditure requirements for at least the next 12 months.

Our future capital requirements will depend on many factors, including our revenue growth rate, the timing and the amount of cash received from customers, the expansion of sales and marketing activities, timing of share repurchases, and the timing and extent of spending to support research and development efforts. Further, we may in the future enter into arrangements to acquire or invest in businesses and technologies. We may be required to seek additional equity or debt financing. In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all. If we are unable to raise additional capital when desired, our business, financial condition, and results of operations could be adversely affected.

We have not entered into any off-balance sheet arrangements and do not have any holdings in variable interest entities.

For further details regarding our cash requirements from noncancelable operating lease obligations and other contractual commitments, see Note 13—Commitments and Contingencies and Note 14—Leases included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

***Cash Flows***

---

| | | |
|:---|:---|:---|
| | **Six Months Ended September 30,** | **Six Months Ended September 30,** |
| | **2025** | **2024** |
| | **(in thousands)** | **(in thousands)** |
| Net cash provided by operating activities | $156045 | $109589 |
| Net cash provided by (used in) investing activities | $(29032) | $54099 |
| Net cash used in financing activities | $(167378) | $(76225) |

---

*Net cash provided by operating activities* 

Cash provided by operating activities was $156.0 million for the six months ended September 30, 2025. This consisted of net income of $115.4 million, adjusted for non-cash items of $60.5 million and a net outflow from operating assets and liabilities of $19.8 million. Non-cash items primarily consisted of stock-based compensation expense of $51.3 million, depreciation and amortization expense of $6.3 million, amortization of deferred contract costs of $6.8 million, and non-cash lease expense of $0.9 million, partially offset by the accretion of discount on marketable securities of $4.7 million. The net outflow from operating assets and liabilities was driven by a $14.3 million decrease in deferred revenue due to the timing of customer billings and program launches, a $4.5 million increase in deferred contract costs, a $2.3 million decrease in accounts payable, accrued expenses, and other liabilities, a $1.1 million decrease in operating lease liabilities, and a $1.0 million increase in accounts receivable due to the timing of billings and collections. The outflows were partially offset by a $3.5 million decrease in prepaid expenses and other assets primarily due to prepaid taxes.

Cash provided by operating activities was $109.6 million for the six months ended September 30, 2024. This consisted of net income of $85.5 million, adjusted for non-cash items of $42.9 million and a net outflow from operating assets and liabilities of $18.8 million. Non-cash items primarily consisted of stock-based compensation expense of $35.0 million, depreciation and amortization expense of $5.2 million, amortization of deferred contract costs of $4.8 million, impairment of long-lived assets of $2.3 million, and non-cash lease expense of $1.0 million, partially offset by the accretion of discount on marketable securities of $5.4 million. The net outflow from operating assets and liabilities was driven by a $23.5 million increase in accounts receivable due to the timing of billings and collections, a $5.5 million decrease in accounts payable, accrued expenses, and other liabilities which was primarily due to the timing of income tax and transferable tax credit payments, a $5.5 million decrease in deferred revenue due to the timing of customer billings and program launches, and a $3.2 million increase in deferred contract costs. The outflows were partially offset by a $19.9 million decrease in prepaid expenses and other assets primarily due to prepaid taxes.

*Net cash provided by (used in) investing activities* 

Cash used in investing activities was $29.0 million for the six months ended September 30, 2025, which primarily consisted of $268.2 million of marketable securities purchases, $26.5 million cash paid for acquisition, and $4.3 million for internal-use software development costs, partially offset by proceeds from the maturities of marketable securities of $270.0 million.

Cash provided by investing activities was $54.1 million for the six months ended September 30, 2024, which primarily consisted of proceeds from the maturities of marketable securities of $417.9 million and $7.2 million of proceeds from the sale of marketable securities, partially offset by $367.8 million of marketable securities purchases and $3.2 million for internal-use software development costs.

*Net cash used in financing activities*

Cash used in financing activities was $167.4 million for the six months ended September 30, 2025, which primarily consisted of common stock repurchases of $144.2 million, $24.5 million of taxes paid related to the net share settlement of equity awards, and $5.2 million of payments for contingent consideration related to the AMiON acquisition. These payments were partially offset by $4.8 million of proceeds from the exercise of stock options and common stock warrants and $1.8 million of proceeds from the issuance of common stock in connection with the employee stock purchase plan.

Cash used in financing activities was $76.2 million for the six months ended September 30, 2024, which primarily consisted of common stock repurchases of $74.2 million, $5.5 million of payments for contingent consideration related to the AMiON acquisition, and $8.2 million of taxes paid related to the net share settlement of equity awards. These payments were partially offset by $10.2 million of proceeds from the exercise of stock options and common stock warrants, and $1.4 million of proceeds from the issuance of common stock in connection with the Company's employee stock purchase plan.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**Critical Accounting Policies and Estimates**

Our condensed consolidated financial statements and the related notes thereto included elsewhere in this Quarterly Report on Form 10-Q are prepared in accordance with GAAP. The preparation of our financial statements also requires us to make estimates and assumptions that affect the amounts stated in the condensed consolidated financial statements and accompanying notes. We base our estimates and judgments on historical experience and on various other assumptions that we believe are reasonable under the circumstances. Actual results could differ significantly from the estimates made by management. To the extent that there are differences between our estimates and actual results, our future financial statement presentation, financial condition, results of operations, and cash flows will be affected.

There have been no material changes to our critical accounting policies and estimates during the three and six months ended September 30, 2025 as compared to those described in the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations" set forth in our Annual Report on Form 10-K for the fiscal year ended March 31, 2025 and filed with the SEC on May 20, 2025.

**Recent Accounting Pronouncements**

Refer to Note 2—Summary of Significant Accounting Policies included in Part I, Item 1 of this Quarterly Report on Form 10-Q for recently adopted accounting pronouncements and recently issued accounting pronouncements not yet adopted.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk**

Substantially all of our operations are within the United States and we do not have any foreign currency exposure. We are exposed to market risks in the ordinary course of our business, including the effects of interest rate changes and inflation.

***Interest Rate Risk***

Our cash and cash equivalents and marketable securities primarily consist of cash on hand and highly liquid investments in money market funds, corporate notes and bonds, commercial paper, and U.S. government and agency securities. As of September 30, 2025, we had cash and cash equivalents of $169.2 million and marketable securities of $709.1 million. We do not enter into investments for trading or speculative purposes. Our investments are exposed to market risk due to fluctuations in interest rates, which may affect our interest income and the fair value of our investments. Fixed rate securities may have their market value adversely affected due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fall short of expectation due to changes in interest rates or we may suffer losses in principal if we are forced to sell securities that decline in market value due to changes in interest rates.

A hypothetical 100 basis point increase in interest rates would have resulted in a decrease of $5.0 million and $5.4 million, respectively, in the market value of our cash equivalents and marketable securities as of September 30, 2025 and March 31, 2025. This estimate is based on a sensitivity model that measures market value changes when changes in interest rates occur. Fluctuations in the value of our investments caused by a change in interest rates are recorded in other comprehensive income and are realized in net income only if we sell the underlying securities.

***Impact of Inflation***

We do not believe that inflation has had a material effect on our business, results of operations, or financial condition. Nonetheless, if our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs. Our inability or failure to do so could harm our business, financial condition, and results of operations.

**Item 4. Controls and Procedures**

**Evaluation of Disclosure Controls and Procedures**

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. In designing and evaluating our disclosure controls and procedures, our management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable assurance that the objectives of the disclosure controls and procedures are met. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective at the reasonable assurance level.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u>

**Changes in Internal Control over Financial Reporting**

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**Inherent Limitations on Effectiveness of Controls**

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u> 

**PART II—OTHER INFORMATION**

**Item 1. Legal Proceedings**

Beginning in April 2024, the Company and certain of our directors and officers have been named in lawsuits in the United States District Court for the Northern District of California. The first lawsuit is captioned In re Doximity, Inc. Securities Litigation, No. 5:24-cv-02281 (N.D. Cal.). The operative complaint brings securities law claims on behalf of a putative class of our investors from June 24, 2021 and August 8, 2023 against the Company and our CEO related to our disclosure of user count and engagement rates. Five shareholder derivative lawsuits have also been filed. Two are consolidated under the caption In re Doximity, Inc. Stockholder Derivative Litigation, No. 5:24-cv-02801 (N.D. Cal.). Two were filed in the United States District Court for the District of Delaware, they are captioned Guttman v. Tangney, et al,. 1:24-cv-01387 (D. Del) and Wong v. Tangney, et al., No. 1:25-cv-750 (D. Del.). One was filed in the Court of Chancery of the State of Delaware with the caption, Stern v. Tangney, et al., No. 2025-0661 (Del. Ch.) The complaints assert claims for, among other things, violations of securities law, breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste against certain of our directors and officers on a similar basis to the securities lawsuit. The securities lawsuit is currently proceeding in the discovery phase. Other similar lawsuits or proceedings may be initiated in the future. The defendants intend to defend vigorously against these actions.

On June 20, 2025, the Company, its Chief Technology Officer and its Director of AI Products were named as defendants in a lawsuit in the U.S. District Court for the District of Massachusetts, captioned OpenEvidence Inc. v. Doximity, Inc. et al., No. 1:25-cv-11802-RGS (D. Mass.). On September 17, 2025, the defendants filed their Answer and Counterclaims, in which they asserted counterclaims against the plaintiff including false advertising in violation of the Lanham Act, the Massachusetts Consumer Protection Law, and common law defamation. On October 29, 2025, the plaintiff amended its Complaint, adding Doximity's subsidiary Pathway Medical, Inc. and certain other individuals as defendants. In its Amended Complaint, the plaintiff alleges the defendants gained unauthorized access to and launched cyberattacks against the defendant's AI medical information platform. The Amended Complaint asserts claims for violation of the Computer Fraud and Abuse Act (CFAA), breach of contract, unjust enrichment, and trespass to chattels. The Amended Complaint dropped several previously asserted claims against the defendants, including a trade secrets claim under the Defend Trade Secrets Act (DTSA). The Amended Complaint requests a permanent injunction enjoining defendants from (i) accessing plaintiff's platform; and (ii) engaging in any further conduct that violates plaintiff's rights; an order to return or destroy the plaintiff's information; actual damages, including lost profits; defendants' profits and unjust enrichment attributable to the alleged misconduct; among other remedies. The defendants intend to defend vigorously against these claims.

For further discussion of our legal proceedings, please refer to Note 13—Commitments and Contingencies included in Part I, Item 1 of this Quarterly Report on Form 10-Q.

**Item 1A. Risk Factors**

Our operations and financial results are subject to various risks and uncertainties, including the factors discussed in this Quarterly Report on Form 10-Q, our consolidated financial statements and the related notes thereto and the sections titled "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" contained in our Annual Report on Form 10-K for the fiscal year ended March 31, 2025 ("Annual Report"),which could adversely affect our business, financial conditions and future results. Other than the risk factors set forth below, there have been no material changes from the risk factors discussed in our Annual Report.

**We may become subject to litigation, which could have a material adverse effect on our business, financial condition, and results of operations.**

We are currently subject to litigation, have been subject to litigation in the past, and may become subject to litigation in the future. Some of these claims may result in significant defense costs and potentially significant judgments against us, some of which we are not, or cannot be, insured against. We generally intend to defend ourselves vigorously; however, we cannot be certain of the ultimate outcomes of any claims currently pending or that may arise in the future. Resolution of these types of matters against us may result in our having to pay significant fines, judgments, or settlements, which, if uninsured, or if the fines, judgments, and settlements exceed insured levels, could adversely impact our earnings and cash flows, thereby having a material adverse effect on our business, financial condition, results of operations, cash flow, and per share trading price of our Class A common stock. Certain litigation or the resolution of certain litigation may affect the availability or cost of some of our insurance coverage, which could adversely impact our results of operations and cash flows, expose us to increased risks that would be uninsured, and adversely impact our ability to attract directors and officers. Certain litigation or the resolution of certain litigation could damage our reputation or relationships with existing or potential customers and employees, make it more difficult to compete effectively and result in a diversion of management's attention and resources, which could have a material adverse effect on our business, financial condition and results of operations.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u> 

**We may seek to grow our business through acquisitions of, or investments in, new or complementary businesses, technologies, tools, or solutions, or through strategic alliances, and the failure to manage these acquisitions, investments or alliances, or to integrate them with our existing business, could have a material adverse effect on us.**

We have completed acquisitions in recent years, including Curative Talent in fiscal 2021, AMiON in fiscal 2023and Pathway Medical in July 2025, and we may in the future consider opportunities to acquire or make additional investments in new or complementary businesses, technologies, offerings, tools, or solutions, or enter into strategic alliances, that may enhance our capabilities and platform in general, complement our current offerings, or expand the breadth of our markets. Our ability to successfully grow through these types of strategic transactions depends upon our ability to identify, negotiate, acquire, and integrate suitable target businesses, technologies, tools, and solutions and to obtain any necessary financing, and is subject to numerous risks, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• failure to identify acquisition, investment, or other strategic alliance opportunities that we deem suitable or available on favorable terms;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• problems integrating the acquired business, technologies, tools, or solutions, including issues maintaining uniform standards, procedures, controls, and policies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• integrating personnel from the acquired company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• unanticipated costs associated with acquisitions, investments, or strategic alliances;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• adverse impacts on our overall margins;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• diversion of management's attention from our existing business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks associated with entering new markets in which we may have limited or no experience;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• potential loss of key employees of acquired businesses; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• increased legal and accounting compliance costs.

In addition, a significant portion of the purchase price of companies we acquire may be allocated to acquired goodwill and other intangible assets. In the future, if our acquisitions do not yield expected returns, we may be required to take impairment charges to our results of operations based on our impairment assessment process, which could harm our results of operations.

We may experience challenges with managing the integration and growth related to these acquisitions or other future acquisitions. The operation and integration of the acquired technologies and business operations may require substantial financial costs and management attention. If we fail to manage such integration processes in a timely and effective manner, our business and financial results may suffer. If we are unable to identify suitable acquisitions or strategic relationships, or if we are unable to integrate any acquired businesses, technologies, tools, and solutions effectively, our business, financial condition, and results of operations could be materially and adversely affected. Also, while we employ several different methodologies to assess potential business opportunities, the new businesses may not meet or exceed our expectations.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

***Unregistered Sales of Equity Securities***

On August 4, 2025, the Company issued 21,500 shares of Class A common stock upon the exercise of the warrant issued to U.S. News & World Report, L.P. in June 2021, at an exercise price of $12.56 per share and aggregate consideration of $270,040.

***Share Repurchases***

The following table presents information with respect to the repurchases of our Class A common stock during the three months ended September 30, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period** | **Total Number of Shares Purchased**<sup>(1)</sup> | **Average Price Paid per Share** | **Total Number of Shares Purchased as Part of Publicly Announced Program**<sup>(1)</sup> | **Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program<br>(in thousands)** |
| July 1 - 31, 2025 | 190948 | $60.16 | 190948 | $290196 |
| August 1 - 31, 2025 | 105896 | $58.86 | 105896 | $283962 |
| September 1 - 30, 2025 | 58394 | $71.39 | 58394 | $279794 |
| Total | 355238 |  | 355238 |  |

---

_______________

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)On May 1, 2024, the Company's board of directors authorized a program to repurchase up to $500 million of the Company's Class A common stock with no expiration date. The repurchases can be executed through open market purchases or privately negotiated transactions, including through Rule 10b5-1 plans.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u> 

**Item 3. Defaults Upon Senior Securities** 

None.

**Item 4. Mine Safety Disclosures**

None.

**Item 5. Other Information**

***Rule 10b5-1 Trading Plans***

None.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u> 

**Item 6. Exhibits.**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| **Exhibit<br>Number** | **Exhibit Title** | **Form** | **File No.** | **Exhibit** | **Filing Date** |
| 3.1 | <u>[Amended and Restated Certificate of Incorporation of the Registrant.](https://www.sec.gov/Archives/edgar/data/1516513/000162828021012207/exhibit32-sx1a1.htm)</u> | S-1/A | 333-256584 | 3.2 | June 15, 2021 |
| 3.2 | <u>[Amended and Restated Bylaws of the Registrant](https://www.sec.gov/Archives/edgar/data/0001516513/000162828021012207/exhibit34-sx1a1.htm)</u> | S-1/A | 333-256584 | 3.4 | June 15, 2021 |
| 4.1 | <u>[Form of Class A common stock certificate of the Registrant.](https://www.sec.gov/Archives/edgar/data/1516513/000162828021011269/exhibit41s-1.htm)</u> | S-1 | 333-256584 | 4.1 | May 28, 2021 |
| 4.2 | <u>[Amended and Restated Investors' Rights Agreement, dated April 10, 2014, by and among the Registrant and certain of its stockholders.](https://www.sec.gov/Archives/edgar/data/1516513/000162828021011269/exhibit42-sx1.htm)</u> | S-1 | 333-256584 | 4.2 | May 28, 2021 |
| 4.3 | <u>[Warrant to Purchase Shares of Common Stock issued to U.S. News & World Report, L.P., dated March 10, 2017.](https://www.sec.gov/Archives/edgar/data/1516513/000162828021011269/exhibit43-sx1.htm)</u> | S-1 | 333-256584 | 4.3 | May 28, 2021 |
| 4.4 | <u>[Warrant to Purchase Shares of Class A Common Stock issued to U.S. News & World Report, L.P., dated June 14, 2021.](https://www.sec.gov/Archives/edgar/data/1516513/000151651321000009/ex-422021usnewswarrantagre.htm)</u> | 10-Q | 001-40508 | 4.2 | August 12, 2021 |
| 4.5 | <u>[Amendment to Warrant to Purchase Shares of Class A Common Stock issued to U.S. News & World Report, L.P., dated September 2, 2021.](https://www.sec.gov/Archives/edgar/data/1516513/000151651321000028/usnwarrantextension.htm)</u> | 10-Q | 001-40508 | 4.3 | November 10, 2021 |
| 4.6 | <u>[Second Amendment to Warrant to Purchase Shares of Class A Common Stock issued to U.S. News & World Report, L.P., dated October 8, 2021.](https://www.sec.gov/Archives/edgar/data/1516513/000151651321000028/usnewswarrantagreementamen.htm)</u>  | 10-Q | 001-40508 | 4.4 | November 10, 2021 |
| 10.1# | <u>[Nate Gross Advisor Agreement](https://www.sec.gov/Archives/edgar/data/1516513/000151651325000093/nategrossica-xjune2025.htm)</u> | 10-Q | 001-40508 | 10.1 | August 7, 2025 |
| 31.1 | <u>[Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](exhibit31193025.htm)</u> | Filed herewith |  |  |  |
| 31.2 | <u>[Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](exhibit31293025.htm)</u> | Filed herewith |  |  |  |
| 32.1\* | <u>[Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](exhibit32193025.htm)</u> | Furnished herewith |  |  |  |
| 32.2\* | <u>[Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](exhibit32293025.htm)</u> | Furnished herewith |  |  |  |
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | Filed herewith |  |  |  |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | Filed herewith |  |  |  |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | Filed herewith |  |  |  |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | Filed herewith |  |  |  |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | Filed herewith |  |  |  |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | Filed herewith |  |  |  |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | Filed herewith |  |  |  |

---

__________________

\* The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the SEC and are not to be incorporated by reference into any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

# Indicates management contract or compensatory plan, contract or agreement.

------

<u>[**Table of Contents**](#i9f5d1bf567c643aa8f278e421a5a7845_7)</u> 

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **DOXIMITY, INC.** | **DOXIMITY, INC.** |
| Date: November 6, 2025 | By: | /s/ Jeffrey Tangney |
|  |  | Jeffrey Tangney<br>Chief Executive Officer<br>*(Principal Executive Officer)* |
| Date: November 6, 2025 | By: | /s/ Anna Bryson |
|  |  | Anna Bryson<br>Chief Financial Officer<br>*(Principal Financial Officer and Principal Accounting Officer)* |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

**PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), AS ADOPTED**

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Jeffrey Tangney, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of Doximity, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | | |
|:---|:---|:---|:---|
| Date: | November 6, 2025 |  |  |
|  |  | By: | /s/ Jeffrey Tangney |
|  |  |  | Chief Executive Officer<br>(Principal Executive Officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a), AS ADOPTED**

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Anna Bryson, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.I have reviewed this Quarterly Report on Form 10-Q of Doximity, Inc.;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | | |
|:---|:---|:---|:---|
| Date: | November 6, 2025 |  |  |
|  |  | By: | /s/ Anna Bryson |
|  |  |  | Chief Financial Officer<br>(Principal Financial Officer and Principal Accounting Officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO** 

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Jeffrey Tangney, Chief Executive Officer of Doximity, Inc. (the "Company"), do hereby certify, to the best of my knowledge and pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** the Quarterly Report on Form 10-Q of the Company for the period ended September 30, 2025 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | | |
|:---|:---|:---|:---|
| Date: | November 6, 2025 |  |  |
|  |  | By: | /s/ Jeffrey Tangney |
|  |  |  | Chief Executive Officer<br>(Principal Executive Officer) |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO** 

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Anna Bryson, Chief Financial Officer of Doximity, Inc. (the "Company"), do hereby certify, to the best of my knowledge and pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** the Quarterly Report on Form 10-Q of the Company for the period ended September 30, 2025 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | | |
|:---|:---|:---|:---|
| Date: | November 6, 2025 |  |  |
|  |  | By: | /s/ Anna Bryson |
|  |  |  | Chief Financial Officer<br>(Principal Financial Officer and Principal Accounting Officer) |

---

<br>